

AP

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
1 August 2002 (01.08.2002)

PCT

(10) International Publication Number
WO 02/059296 A2(51) International Patent Classification⁷: C12N 15/10

(21) International Application Number: PCT/DK02/00055

(22) International Filing Date: 25 January 2002 (25.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2001 00127 25 January 2001 (25.01.2001) DK
60/301,022 27 June 2001 (27.06.2001) US(71) Applicant (for all designated States except US): EVOLVA
BIOTECH A/S [DK/DK]; Fruebjergvej 3, DK-2100
Copenhagen Ø (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GOLDSMITH,
Neil [GB/GB]; 17 Southfield Road, Oxford OX4 1NX
(GB). SØRENSEN, Alexandra, M., P., Santa Ana
[DK/DK]; Østre Paradisvej 5D, st.th., DK-2840 Holte
(DK). NIELSEN, Søren, V., S. [DK/DK]; Høveltsvangvej
72, DK-3450 Allerød (DK). NAESBY, Michael [DK/DK];
Panumsvej 23, DK-2500 Valby (DK).(74) Agent: HØIBERG APS; Store Kongensgade 59 B,
DK-1264 Copenhagen K. (DK).(81) Designated States (national): AE, AG, AL, AM, AT (util-
ity model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ (utility model), DE (utility model),
DK (utility model), DM, DZ, EC, EE (utility model), ES,
FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM,
PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model),
SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZM, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that reportFor two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CONCATEMERS OF DIFFERENTIALLY EXPRESSED MULTIPLE GENES

(57) Abstract: In the present invention are disclosed concatemers of concatenated expression cassettes and vectors that enable the synthesis of such concatemers. The main purpose of these concatemers is the controllable and co-ordinated expression of large numbers of heterologous genes in a single host. Furthermore, the invention relates to a concatemers of cassettes of nucleotide sequences and a method for preparing the concatemers. In a further aspect, the invention relates to transgenic host cells comprising at least one concatemer according to the invention, as well as to a method for preparing the transgenic host cells. Finally, the invention relates to a vector comprising a cassette of nucleotides, a method for preparing said vector, a nucleotide library comprising at least two primary vectors each comprising a cassette of nucleotides, a method for preparing the library.

WO 02/059296 A2

Concatemers of differentially expressed multiple genes.

5 This application is a nonprovisional of U.S. provisional application Serial No. 60/301,022 filed 27. June 2001; which is hereby incorporated by reference in its entirety. The application claims priority from Danish patent application number PA 2001 00127 filed 25. January 2001, which is hereby incorporated by reference in its entirety. All patent and nonpatent references cited in the application, or in the present application, are also hereby incorporated by reference in their entirety.

10 In the present invention are disclosed concatemers of concatenated expression cassettes and vectors that enable the synthesis of such concatemers. The main purpose of these concatemers is the controllable and co-ordinated expression of large numbers of heterologous genes in a single host cell. Furthermore, the invention relates to a concatemer of cassettes of nucleotide sequences and a
15 method for preparing the concatemers. In a further aspect, the invention relates to transgenic host cells comprising at least one concatemer according to the invention, as well as to a method for preparing the transgenic host cells. Finally, the invention relates to a vector comprising a cassette of nucleotides, a method for preparing said vector, a nucleotide library comprising at least two primary vectors each comprising
20 a cassette of nucleotides, a method for preparing the library.

Prior art

25 The design of expression constructs and expression libraries is well known in the art.

WO 96/34112 discloses a combinatorial gene expression library with a pool of expression constructs each construct containing a cDNA or genomic DNA fragment from a plurality of donor organisms. The DNA fragments are operably associated
30 with regulatory regions that drive expression in a host cell. The publication also discloses a combinatorial gene expression library in which each cell comprises a concatemer of cDNA fragments being operably associated with regulatory regions to drive expression of the genes encoded by the concatenated cDNA in a host organism. The host organism may be a yeast cell. The vector used for constructing
35 the library may be a plasmid vector, a phage, a viral vector, a cosmid vector or an

artificial chromosome (BAC or YAC). Suitable promoters include natural and synthetic promoters as well as constitutive and inducible promoters.

5 The genes used for the the concatemers are prepared in a highly ordered multi-step procedure consisting of a number of discrete reaction steps. First, cDNA inserts are prepared using PCR and methylated dCTP to protect internal Not I and Bam HI restriction sites from later digestion. Promoter and terminator fragments are ligated to the 5' and 3' ends respectively using modified Bam HI adapters. The gene cassettes have the basic structure: promoter-coding sequence-terminator with
10 different restriction sites in each end. The restriction site in the 3' end is protected. Similar gene cassettes can be prepared from genomic DNA which is randomly fragmented using a restriction enzyme.

15 The concatemers disclosed in WO 96/34112 are prepared in a highly ordered multi-step procedure, where the first gene cassette is ligated to an adapter nucleotide sequence linked to a bead having a blunt end corresponding to the blunt 5' end of the gene cassette. After ligation, the restriction site is no longer functional, since it was assembled using two compatible but not identical restriction sites. After linking the first gene cassette to the bead, the protected restriction site in the 3' end is
20 "opened" and the second gene cassette is linked to the first. After 5 to 10 rounds of ligation of gene cassettes, the vector is ligated to the 3' end of the concatemer, the concatemer-vector construct is liberated from the bead and the 5' end is ligated to the other end of the vector. It is emphasised that the 3' and 5' ends of the concatemer should be non-compatible to avoid self assembly during cloning into the
25 vector.

Due to the plurality of discrete steps in the preparation procedure, the method is not suitable for preparing concatemers of significantly larger size. Once the gene cassettes have been cloned into the vector, it is not possible to excise the cassettes
30 or the complete concatemer from the vector using a restriction enzyme.

US 6,057,103 (Diversa) discloses a method for identification of clones having a specified enzyme activity through isolation of DNA from a microorganism and hybridisation with a probe DNA comprising at least part of a sequence encoding an
35 enzyme having a specified activity. The identified sequences are linked to a

promoter sequence (e.g. eukaryotic promoters: CMV immediate/early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I) and inserted into a vector, which may be a YAC or a P1 based artificial chromosome. Host cells used for transformation with the identified nucleotide sequences include bacterial cells, yeast, insect cells, mammalian cells. The disclosed vectors are not adapted for cloning of high numbers of expressible nucleotide sequences, and the reference does not disclose the concatemers for cloning of multiple genes into a host cell. More specifically the reference does not render possible the combination and screening of combinations of genes under conditions that allow genes to be combined in new ways.

US 5,958,672 (Diversa) discloses a method for identifying protein activity of interest by culturing a gene expression library obtained from uncultivated microorganisms (or lower eukaryotic species). The gene expression library may be obtained from genomic DNA or from cDNA. The DNA clones are controllably associated to regulatory sequences, which drive the expression of the sequences in the host cell. The libraries may be screened against a DNA probe as described in US 6,054,267. As is the case in the other references cited above, the combination of genes isolated from the uncultivated micro-organisms is a static combination. Once, the isolated genes are inserted into the host cells, no further gene combinations and no further optimisation of gene combinations are intended.

It is one objective of the present invention to provide methods and vectors for cloning of large numbers of expressible nucleotide sequences, which are especially adapted for later random ligation into concatemers, which can in turn be inserted into an expression host for expression of the genes in the concatemer or a sub-set of the genes or of different sub-sets of the genes in the concatemer. Thereby it becomes possible to optimise combinations of expressible nucleotide sequences for any screenable trait.

It is a further objective of the present invention to provide methods and vectors, which allow for the production of concatemers, which are flexible. By flexible in this context is meant, that the gene cassettes of the concatemers can be disassembled and reassembled easily using standard molecular techniques, such as excision by the use of restriction enzymes.

Summary of the invention

According to a first aspect the invention relates to a nucleotide concatemer comprising in the 5'→3' direction a cassette of nucleotide sequence of the general formula

$[rs_2-SP-PR-X-TR-SP-rs_1]_n$

wherein

rs₁ and rs₂ together denote a restriction site,
SP individually denotes a spacer of at least two nucleotide bases,
PR denotes a promoter, capable of functioning in a cell,
X denotes an expressible nucleotide sequence,
TR denotes a terminator, and
SP individually denotes a spacer of at least two nucleotide bases, and
n ≥ 2, and
wherein at least a first cassette is different from a second cassette.

The concatemers according to the invention may comprise a selection of expressible nucleotide sequences from just one expression state and can thus be assembled from one library representing this expression state or it may comprise cassettes from a number of different expression states mixed in any suitable ratio. The concatemers according to the invention are especially suitable for ligating into an artificial chromosome, which may be inserted into a host cell for coordinated expression. For this purpose, the variation among and between cassettes may be such as to minimise the chance of cross over as the host cell undergoes cell division such as through minimising the level of repeat sequences occurring in any one concatemer, since it is not an object of this embodiment of the invention to obtain recombination of concatemers with a segment in the host genome or an epitope of the host cells or any intraconcatemer recombination.

The concatemers can be used to make novel and non-native combinations of genes for co-ordinated expression in a host cell. Thereby new metabolic pathways can be generated, which may lead to the production of new metabolites, and/or to the metabolism of compounds, which are otherwise not metabolisable by the host cells. The new gene combinations may also lead to metabolic pathways which

produce metabolites in new quantities or in new compartments of the cell or outside the cell. Depending on the purpose, the selection of genes can be made completely random based on sourcing of expressible nucleotide sequences across the different kingdoms. However, it may also be advantageous to source genes from sources
5 known to have certain metabolic pathways in order to make targeted new gene combinations. It may also be advantageous to source genes from organisms/tissues known to have relevant properties, e.g. pharmaceutical activity.

One of several advantages of the concatemers of the present invention is that the
10 expression cassettes can be cut out from the concatemers at any point to make new combinations of expression cassettes. During re-assembly, further genes comprised in similar expression cassettes may be added if desired to modify the expression pattern. In this way, the concatemers according to the present invention present a powerful tool in generating novel gene combinations.

15 One advantage of the structure of the concatemer is that cassettes can be recovered from the host cell through nucleotide isolation and subsequent digestion with a restriction enzyme specific for the rs_1 - rs_2 restriction site. The building blocks of the concatemers may thus be disassembled and reassembled at any point.

20 The cassettes of the concatemer may be joined head to tail or head to head or tail to tail, which does not affect expression of the expressible nucleotide sequences because each expressible nucleotide sequence is under the control of its own promoter. This is due to the fact that most restriction enzymes leave two identical
25 overhangs, which may combine in either orientation at the same frequency.

However the restriction sites can also be selected so that head to tail arrangement is favoured, for example by using restriction enzymes that generate non-palindromic overhangs. Examples of such enzymes are listed in example 6c and most of the
30 enzymes in 6d. Non-palindromic overhangs will prevent head to head and tail to tail ligation. By the use of two or more different entry vectors, the sequence of the cutting region can be designed to yield different overhangs after digestion with a single of these enzymes. Examples of such enzymes are most of the enzymes in example 6c and one in 6d, and have variable nucleotides (N or W) in the overhang. In this
35 way a cassette can be excised with one enzyme that has non-identical overhangs.

This will prevent intramolecular religation and prevent that identical cassettes ligate to each other, decreasing the risk of intramolecular recombination.

5 The invention in a further aspect relates to a method for concatenation comprising the steps of concatenating at least two cassettes of nucleotide sequences each cassette comprising a first sticky end, a spacer sequence, a promoter, an expressible nucleotide sequence, a terminator, and a second sticky end.

10 Preferably, the method comprises starting from primary vectors comprising a cassette having the following nucleotide sequence

[RS1-RS2-SP-PR-X-TR-SP-RS2'-RS1'],

wherein X denotes an expressible nucleotide sequence,

RS1 and RS1' denote restriction sites,

RS2 and RS2' denote restriction sites different from RS1 and RS1',

15 SP individually denotes a spacer sequence of at least two nucleotides,

PR denotes a promoter,

TR denotes a terminator,

20 i) cutting the primary vector with the aid of at least one restriction enzyme specific for RS2 and RS2' obtaining cassettes having the general formula [rs₂-SP-PR-X-TR-SP-rs₁] wherein rs₁ and rs₂ together denote a functional restriction site RS2 or RS2',

ii) assembling the cut out cassettes through interaction between rs₁ and rs₂.

25 According to this embodiment, excision and concatenation is carried out in a "one step" reaction, i.e. without an intervening purification step, starting from vectors containing the expression cassettes. The expression cassettes can be cut out using two restriction enzymes specific for RS1 and RS2. Preferably for this one step reaction RS1 leaves blunt ends and RS2 leaves sticky ends. Upon addition of a ligase, the concatemer can be assembled in the mixture without any need for purification, since the vector backbone and the small RS1-RS2 fragments do not
30 interfere with the concatenation reaction.

In the case, where the concatemer is to be inserted into an artificial chromosome vector for later transformation into an expression host cell, the AC vector arms can be added directly to the concatenation reaction mixture, so that the complete
35 artificial chromosome vector containing the concatemer can be assembled in one

step. By controlling the ratio of vector arms to cassettes, the size of the concatemer can be controlled. It is of course also possible to control the size of the concatemers by adding stopper fragments, the stopper fragments each having a RS2 or RS2' in one end and a non-complementary overhang or a blunt end in the other end. Vector arms may also be added later on in a separate step.

Advantageously, the method comprises addition of vector arms each having a RS2 or RS2' in one end and a non-complementary overhang or a blunt end in the other end. These can be added to the concatenation mixture, and even in this complex mixture, concatemers with one vector arm in each end will be produced under appropriate conditions. Host cells transformed with the desired construction, including the appropriate vector arms, can be selected by utilizing marker genes present on the arms.

In one aspect the invention relates to a host cell, which comprises at least one concatemer of individual oligonucleotide cassettes, each concatemer comprising oligonucleotide of the following formula in 5'→3' direction: $[rs_2\text{-}SP\text{-}PR\text{-}X\text{-}TR\text{-}SP\text{-}rs_1]_n$, wherein rs_1 and rs_2 together denote a restriction site, SP individually denotes a spacer of at least two nucleotide bases, PR denotes a promoter, capable of functioning in the cell, X denotes an expressible nucleotide sequence, TR denotes a terminator, and SP individually denotes a spacer of at least two nucleotide bases, wherein $n \geq 2$, and wherein at least two expressible nucleotide sequences are from different expression states.

In another aspect the invention relates to a cell comprising at least one concatemer of individual oligonucleotide cassettes, each concatemer comprising oligonucleotide of the following formula in 5'→3' direction:

$[rs_2\text{-}SP\text{-}PR\text{-}X\text{-}TR\text{-}SP\text{-}rs_1]_n$

wherein

rs_1 and rs_2 together denote a restriction site,
SP individually denotes a spacer of at least two nucleotide bases,
PR denotes a promoter, capable of functioning in the cell,
X denotes an expressible nucleotide sequence,
TR denotes a terminator, and
SP individually denotes a spacer of at least two nucleotide bases,

wherein $n \geq 2$, and

wherein rs_1 - rs_2 in at least two cassettes is recognised by the same restriction enzyme.

5 Thereby non-naturally occurring combinations of expressible genes can be combined in one cell in such a way that co-ordinated expression of a subset of genes is made possible or all the inserted genes may be expressed at the same time. Through external regulation of the promoters controlling the expressible nucleotides sequences novel and non-naturally occurring combinations of
10 expressed genes can be obtained. Since these novel and non-natural combinations of gene products are found in one and the same cell, the heterologous gene products may affect the metabolism of the host cell in novel ways and thus cause it to produce novel and/or non-native primary or secondary metabolites and/or known metabolites in novel amounts and/or known metabolites in novel compartments of
15 the cell or outside the cells. The novel metabolic pathways and/or novel or modified metabolites may be obtained without substantially recombining the introduced genes with any segment in the host genome or any episome of the host cells.

20 The cells containing the concatemers, preferably in the form of artificial chromosomes, may be used for directed evolution by subjecting populations of cells to selective conditions. One advantage of the structure of the concatemers is that expression cassettes from different cells or from different populations of cells can be combined easily in a few steps thereby increasing the potential of the evolution. When the concatemers are inserted in the form of artificial chromosomes, evolution
25 may also be carried out using traditional breeding and selection.

30 It is likely that through the combination of a high number of non-native genes in a host cell combinations of genes or single genes are inserted that are lethal or sub-lethal to the host cell. Through the co-ordinated expression of the genes in the host cell it is possible not only to induce the expression of any subset of genes but also to repress such expression, e.g. of lethal or sub-lethal genes.

35 By producing cells with combinations of concatemers comprising cassettes with expressible nucleotide sequences from a number of different expression states, which may be from any number of expression states, from the same or from

selected species, from unrelated or distantly related species, or from species from different kingdoms, novel and random combinations of gene products are produced in one single cell. By furthermore having expressible nucleotide sequences under the control of a number of independently inducible or repressible promoters, a large number of different expression states can be created inside one single cell by selectively turning on and off groups of the inserted expressible nucleotide sequences. The number of independently inducible and/or repressible promoters in one cell may vary from 1 to 100, 1 to 50, 1 to 10, or such as up to 15, 20, 25 or above 50 promoters.

By inserting novel genes into the host cell, and especially by inserting a high number of novel genes from a wide variety of species into a host cell, it is highly likely that the gene products from this array of novel genes will interact with the pool of metabolites of the host cell and modify known metabolites and/or intermediates in novel ways to create novel compounds. Since the interaction is performed at the enzyme level it is furthermore likely that the result will be novel compounds with chiral centres, which are especially difficult to synthesise via chemical synthesis.

Novel metabolic pathways may also be made that are not capable of functioning, due to the absence of a substrate in the host cell. Such metabolic pathways may be made active by addition of non-host-cell specific substrates, which are metabolisable by the novel pathways.

One special advantage of the cells according to the present invention, is that incompatibility barriers between species do not limit the combinations of genes in one single cell.

According to a further aspect the invention relates to a method for producing a transgenic cell comprising inserting into a host cell a concatemer comprising a heterologous nucleotide sequence comprising at least two genes each controlled by a promoter, wherein the two genes and/or the two promoters are different.

According to a further aspect, the invention concerns a primary vector comprising a nucleotide sequence cassette of the general formula in 5'→3' direction:

[RS1-RS2-SP-PR-CS-TR-SP-RS2'-RS1']

10

wherein

RS1 and RS1' denote restriction sites,

RS2 and RS2' denote restriction sites different from RS1 and RS1',

SP individually denotes a spacer sequence of at least two nucleotides,

5 PR denotes a promoter,

CS denotes a cloning site,

TR denotes a terminator.

10 The cassette within the primary vector is useful for cloning and storing in a host cell random expressible nucleotide sequences, which are under the control of the promoter comprised in the cassette. The cassette may be inserted and removed by using restriction enzymes specific for either of the four restriction sites, of which RS1 and RS1' are preferably identical and RS2 and RS2' are also preferably identical. One special advantage of the cassette is that a collection of cassettes may be
15 assembled into a concatemer of cassettes according to the invention by excising the cassettes from the primary vector, e.g. through use of the restriction enzyme(s) specific for RS2 and RS2', and concatenation of a population of random cassettes in a solution. The easiest concatenation is obtained when RS1 and RS1' leave blunt ends and RS2 and RS2' leave sticky ends. In this way it can be avoided that the
20 empty vector takes part in the concatenation. Furthermore, it has been observed that the small fragments containing RS1-RS2 and RS1'-RS2' do not have to be removed, since they do not interfere with the concatenation. If desired, the small fragments can easily be removed using e.g. precipitation or filtration.

25 The primary vector according to the invention is especially adapted for expression with cDNA into it, because it is equipped with a promoter. Integration of genomic DNA is also possible however this may cause interaction between the native promoter sequences of the inserted genomic DNA and the external control obtainable through the promoter of the vector.

30 Preferably, PR is not functional in the host of the primary vector but only functional in the expression host, into which the concatemers are going to be inserted for expression. This is to avoid selection against genes which are lethal to the library host, in which the primary vector is stored and/or amplified.

35

The spacer sequence is inserted in the cassette in order to increase stability of the concatemers after concatenation. The cassettes are built so that they can be joined head to tail, head to head or tail to tail after concatenation. A concatemer of two cassettes can thus have the following structure:

5

3' rs₂-SP-PR-X-TR-SP-rs₁-rs₂-SP-PR-X-TR-SP-rs₁ 5'

3' rs₂-SP-TR-X-PR-SP-rs₁-rs₂-SP-PR-X-TR-SP-rs₁ 5'

3' rs₂-SP-PR-X-TR-SP-rs₁-rs₂-SP-TR-X-PR-SP-rs₁ 5'

10

(rs₁-rs₂ together denote a restriction site)

The presence of the spacer reduces the risk of hairpin formation between two adjacent terminator or promoter sequences, which may be identical. As a consequence, the presence of the spacer is also intended to increase the stability of the concatemers in the expression host into which they are inserted.

15

Using enzymes that leave non-palindromic overhangs it is possible to generate concatemers with essentially head to tail orientation.

20

In another aspect the invention relates to a method of preparing a primary vector comprising

inserting an expressible nucleotide sequence into a cloning site in a primary vector comprising a cassette, the cassette comprising a nucleotide sequence of the general formula in 5'→3' direction:

25

[RS1-RS2-SP-PR-CS-TR-SP-RS2'-RS1']

wherein

RS1 and RS1' denote restriction sites,

RS2 and RS2' denote restriction sites different from RS1 and RS1',

SP individually denotes a spacer sequence of at least two nucleotides,

30

PR denotes a promoter,

CS denotes a cloning site, and

TR denotes a terminator.

In a further aspect the invention relates to a nucleotide library comprising at least two primary vectors each vector comprising a nucleotide sequence cassette of the general formula in 5'→3' direction:

[RS1-RS2-SP-PR-X-TR-SP-RS2'-RS1']

5

wherein

RS1 and RS1' denote restriction sites,

RS2 and RS2' denote restriction sites different from RS1 and RS1',

SP individually denotes a spacer sequence of at least two nucleotides,

PR denotes a promoter,

10

X denotes an expressible nucleotide sequence,

TR denotes a terminator.

— wherein the expressible nucleotide sequences are isolated from one expression state, and

— wherein at least two cassettes are different.

15

The nucleotide library may also be referred to as an entry (=initial) library, the intention being to use the nucleotide library as a suitable means for storing and amplifying a high number of vectors comprising the nucleotide cassettes according to the invention. It is also intended to excise the cassettes after amplification in order to use the excised cassettes for concatenation. Conveniently one nucleotide library may cover expressible nucleotide sequences from the same source pool, such as from the same expression state. Therefore, the library is conveniently used for introducing cDNA synthesised from mRNA isolated from one expression state.

20

25

Preferably, the PR sequences are not capable of functioning in the library host cells. This is to ensure that none of the expressible nucleotide sequences are lethal to the library host cell and therefore may be lost.

30

The nucleotide library furthermore provides a suitable means for later assembly of concatemers of cassettes stored in the library. According to an especially preferred embodiment of the invention, substantially all cassettes in the library are different. This difference is partly introduced to be able to coordinately express different subset of genes and partly to minimise the level of repeat sequences occurring in the concatemers.

35

In a still further aspect the invention relates to a method for preparing a nucleotide library comprising obtaining expressible nucleotide sequences, cloning the expressible nucleotide sequences into cloning sites of a mixture of primary vectors, the primary vectors comprising a cassette, the cassettes comprising a nucleotide sequence of the general formula in 5'→3' direction:

[RS1-RS2-SP-PR-CS-TR-SP-RS2'-RS1']

wherein

RS1 and RS1' denote restriction sites,

RS2 and RS2' denote restriction sites different from RS1 and RS1',

SP individually denotes a spacer sequence of at least two nucleotides,

PR denotes a promoter,

CS denotes a cloning site, and

TR denotes a terminator,

and transferring the primary vectors into a host cell obtaining a library.

Conveniently the method may comprise building a cDNA library from mRNA isolated from one expression state or starting from a cDNA library and cloning the cDNA sequences into a mixture of primary vectors according to the invention. In order to have the library and sub-libraries organised in a proper manner, each library comprises expressible nucleotide sequences representative of a given expression state.

For all the concatemers and libraries discussed herein the spacers (SP, promoters (PR), and terminators (TR) may be identical in all cassettes, but in preferred embodiments the spacers (SP, promoters (PR), and terminators (TR) are different for at least a part of the cassettes in a concatemer and a library.

Brief description of the drawings

Fig. 1 shows a flow chart of the steps leading from an expression state to incorporation of the expressible nucleotide sequences in an entry library (a nucleotide library according to the invention).

Fig. 2 shows a flow chart of the steps leading from an entry library comprising expressible nucleotide sequences to evolvable artificial chromosomes (EVAC)

transformed into an appropriate host cell. Fig. 2a shows one way of producing the EVACs which includes concatenation, size selection and insertion into an artificial chromosome vector. Fig. 2b shows a one step procedure for concatenation and ligation of vector arms to obtain EVACs.

5

Fig. 3 shows a model entry vector. MCS is a multi cloning site for inserting expressible nucleotide sequences. Amp R is the gene for ampicillin resistance. Col E is the origin of replication in *E. coli*. R1 and R2 are restriction enzyme recognition sites.

10

Fig. 4 shows an example of an entry vector according to the invention, EVE4. MET25 is a promoter, ADH1 is a terminator, f1 is an origin of replication for filamentous phages, e.g. M13. Spacer 1 and spacer 2 are constituted by a few nucleotides deriving from the multiple cloning site, MCS, SrfI and Ascl are restriction enzyme recognition sites. Other abbreviations, see Fig. 3. The sequence of the vector is set forth in SEQ ID NO 1.

15

20

Fig 5 shows an example of an entry vector according to the invention, EVE5. CUP1 is a promoter, ADH1 is a terminator, f1 is an origin of replication for filamentous phages, e.g. M13. Spacer 1 and spacer 2 are constituted by a few nucleotides deriving from the multiple cloning site, MCS, SrfI and Ascl are restriction enzyme recognition sites. Other abbreviations, see Fig. 3. The sequence of the vector is set forth in SEQ ID NO 2.

25

30

Fig 6 shows an example of an entry vector according to the invention, EVE8. CUP1 is a promoter, ADH1 is a terminator, f1 is an origin of replication for filamentous phages, e.g. M13. Spacer3 is a 550 bp fragment of lambda phage DNA fragment. Spacer4 is a ARS1 sequence from yeast. SrfI and Ascl are restriction enzyme recognition sites. Other abbreviations, see Fig. 3. The sequence of the vector is set forth in SEQ ID NO 3.

35

Fig. 7 shows a vector (pYAC4-Ascl) for providing arms for an evolvable artificial chromosome (EVAC) into which a concatemer according to the invention can be cloned. TRP1, URA3, and HIS3 are yeast auxotrophic marker genes, and AmpR is an *E. coli* antibiotic marker gene. CEN4 is a centromere and TEL are telomeres.

ARS1 and PMB1 allow replication in yeast and *E. coli* respectively. BamH I and Asc I are restriction enzyme recognition sites. The nucleotide sequence of the vector is set forth in SEQ ID NO 4.

- 5 Fig 8. shows the general concatenation strategy. On the left is shown a circular entry vector with restriction sites, spacers, promoter, expressible nucleotide sequence and terminator. These are excised and ligated randomly.

Lane	F/Y
1	100/1
2	50/1
3	20/1
4	10/1
5	5/1
6	2/1
7	1/1
8	1/2
9	1/5

- 10 Legend: Lane M: molecular weight marker, λ -phage DNA digested w. Pst1. Lanes 1-9, concatenation reactions. Ratio of fragments to yac-arms(F/Y) as in table.

- Fig 9a and 9b. illustrates the integration of concatenation with synthesis of evolvable artificial chromosomes and how concatemer size can be controlled by controlling the ratio of vector arms to expression cassettes, as described in example 7.

- Fig 10. Library of EVAC transformed population shown under 4 different growth conditions. Coloured phenotypes can be readily detected upon induction of the Met25 and/or the Cap1 promoters.

20

- Fig 11. EVAC gel Legend: PFGE of EVAC containing clones :
 Lanes. a: Yeast DNA PFGE markers(strain YNN295), b: lambda ladder, c: non-transformed host yeast, 1 – 9 : EVAC containing clones. EVACs in size range 1400-1600 kb. Lane 2 shows a clone containing 2 EVACs sized ~1500 kb and ~550 kb respectively. The 550kb EVAC is comigrating with the 564kb yeast chromosome and is resulting in an increased intensity of the band at 564 kb relative to the other bands in the lane. Arrows point up to EVAC bands.

25

Definitions

Oligonucleotides

Any fragment of nucleic acids having approximately from 2 to 10000 nucleic acids.

5

Restriction site

For the purposes of the present invention the abbreviation RS_n (n=1,2,3, etc) is used to designate a nucleotide sequence comprising a restriction site. A restriction site is defined by a recognition sequence and a cleavage site. The cleavage site may be located within or outside the recognition sequence. The abbreviation "rs₁" or "rs₂" is used to designate the two ends of a restriction site after cleavage. The sequence "rs₁-rs₂" together designate a complete restriction site.

10

The cleavage site of a restriction site may leave a double stranded polynucleotide sequence with either blunt or sticky ends. Thus, "rs₁" or "rs₂" may designate either a blunt or a sticky end.

15

In the notation used throughout the present invention, formulae like:

RS1-RS2-SP-PR-X-TR-SP-RS2-RS1

20

should be interpreted to mean that the individual sequences follow in the order specified. This does not exclude that part of the recognition sequence of e.g. RS2 overlap with the spacer sequence, but it is a strict requirement that all the items except RS1 and RS1' are functional and remain functional after cleavage and re-assembly. Furthermore the formulae do not exclude the possibility of having additional sequences inserted between the listed items. For example introns can be inserted as described in the invention below and further spacer sequences can be inserted between RS1 and RS2 and between TR and RS2. Important is that the sequences remain functional.

25

Furthermore, when reference is made to the size of the restriction site and/or to specific bases within it, only the bases in the recognition sequence are referred to.

30

Expression state

An expression state is a state in any specific tissue of any individual organism at any one time. Any change in conditions leading to changes in gene expression leads to

35

another expression state. Different expression states are found in different individuals, in different species but they may also be found in different organs in the same species or individual, and in different tissue types in the same species or individual. Different expression states may also be obtained in the same organ or tissue in any one species or individual by exposing the tissues or organs to different environmental conditions comprising but not limited to changes in age, disease, infection, drought, humidity, salinity, exposure to xenobiotics, physiological effectors, temperature, pressure, pH, light, gaseous environment, chemicals such as toxins.

10 Artificial chromosome

As used herein, an artificial chromosome (AC) is a piece of DNA that can stably replicate and segregate alongside endogenous chromosomes. For eukaryotes the artificial chromosome may also be described as a nucleotide sequence of substantial length comprising a functional centromere, functional telomeres, and at least one autonomous replicating sequence. It has the capacity to accommodate and express heterologous genes inserted therein. It is referred to as a mammalian artificial chromosome (MAC) when it contains an active mammalian centromere. Plant artificial chromosome and insect artificial chromosome (BUGAC) refer to chromosomes that include plant and insect centromeres, respectively. A human artificial chromosome (HAC) refers to a chromosome that includes human centromeres, AVACs refer to avian artificial chromosomes. A yeast artificial chromosome (YAC) refers to chromosomes are functional in yeast, such as chromosomes that include a yeast centromere.

25 As used herein, stable maintenance of chromosomes occurs when at least about 85%, preferably 90%, more preferably 95% of the cells retain the chromosome. Stability is measured in the presence of a selective agent. Preferably these chromosomes are also maintained in the absence of a selective agent. Stable chromosomes also retain their structure during cell culturing, suffering neither intrachromosomal nor interchromosomal rearrangements.

Detailed description of the invention

In the following the invention is described in the order in which the steps of obtaining a transformed host cell containing an evolvable artificial chromosome may be performed, starting with the entry vector.

Origin of expressible nucleotide sequences

The expressible nucleotide sequences that can be inserted into the vectors, concatemers, and cells according to this invention encompass any type of nucleotide such as RNA, DNA. Such a nucleotide sequence could be obtained e.g. from cDNA, which by its nature is expressible. But it is also possible to use sequences of genomic DNA, coding for specific genes. Preferably, the expressible nucleotide sequences correspond to full length genes such as substantially full length cDNA, but nucleotide sequences coding for shorter peptides than the original full length mRNAs may also be used. Shorter peptides may still retain the catalytic activity similar to that of the native proteins.

Another way to obtain expressible nucleotide sequences is through chemical synthesis of nucleotide sequences coding for known peptide or protein sequences. Thus the expressible DNA sequences does not have to be a naturally occurring sequence, although it may be preferable for practical purposes to primarily use naturally occurring nucleotide sequences. Whether the DNA is single or double stranded will depend on the vector system used.

In most cases the orientation with respect to the promoter of an expressible nucleotide sequence will be such that the coding strand is transcribed into a proper mRNA. It is however conceivable that the sequence may be reversed generating an antisense transcript in order to block expression of a specific gene.

Cassettes

An important aspect of the invention concerns a cassette of nucleotides in a highly ordered sequence, the cassette having the general formula in 5'→3' direction:

[RS1-RS2-SP-PR-CS-TR-SP-RS2'-RS1']

wherein RS1 and RS1' denote restriction sites, RS2 and RS2' denote restriction sites different from RS1 and RS1', SP individually denotes a spacer sequence of at least two nucleotides, PR denotes a promoter, CS denotes a cloning site, and TR denotes a terminator.

5

It is an advantage to have two different restriction sites flanking both sides of the expression construct. By treating the primary vectors with restriction enzymes cleaving both restriction sites, the expression construct and the primary vector will be left with two non-compatible ends. This facilitates a concatenation process, since the empty vectors do not participate in the concatenation of expression constructs.

10

Restriction sites

In principle, any restriction site, for which a restriction enzyme is known can be used. These include the restriction enzymes generally known and used in the field of molecular biology such as those described in Sambrook, Fritsch, Maniatis, "A laboratory Manual", 2nd edition. Cold Spring Harbor Laboratory Press, 1989.

15

The restriction site recognition sequences preferably are of a substantial length, so that the likelihood of occurrence of an identical restriction site within the cloned oligonucleotide is minimised. Thus the first restriction site may comprise at least 6 bases, but more preferably the recognition sequence comprises at least 7 or 8 bases. Restriction sites having 7 or more non N bases in the recognition sequence are generally known as "rare restriction sites" (see example 6). However, the recognition sequence may also be at least 10 bases, such as at least 15 bases, for example at least 16 bases, such as at least 17 bases, for example at least 18 bases, such as at least 18 bases, for example at least 19 bases, for example at least 20 bases, such as at least 21 bases, for example at least 22 bases, such as at least 23 bases, for example at least 25 bases, such as at least 30 bases, for example at least 35 bases, such as at least 40 bases, for example at least 45 bases, such as at least 50 bases.

20

25

30

Preferably the first restriction site RS1 and RS1' is recognised by a restriction enzyme generating blunt ends of the double stranded nucleotide sequences. By generating blunt ends at this site, the risk that the vector participates in a

35

subsequent concatenation is greatly reduced. The first restriction site may also give rise to sticky ends, but these are then preferably non-compatible with the sticky ends resulting from the second restriction site, RS2 and RS2' and with the sticky ends in the AC.

5

According to a preferred embodiment of the invention, the second restriction site, RS2 and RS2' comprises a rare restriction site. Thus, the longer the recognition sequence of the rare restriction site the more rare it is and the less likely is it that the restriction enzyme recognising it will cleave the nucleotide sequence at other – undesired – positions.

10

The rare restriction site may furthermore serve as a PCR priming site. Thereby it is possible to copy the cassettes via PCR techniques and thus indirectly "excise" the cassettes from a vector.

15

Spacer sequence

The spacer sequence located between the RS2 and the PR sequence is preferably a non-transcribed spacer sequence. The purpose of the spacer sequence(s) is to minimise recombination between different concatemers present in the same cell or between cassettes present in the same concatemer, but it may also serve the purpose of making the nucleotide sequences in the cassettes more "host" like. A further purpose of the spacer sequence is to reduce the occurrence of hairpin formation between adjacent palindromic sequences, which may occur when cassettes are assembled head to head or tail to tail. Spacer sequences may also be convenient for introducing short conserved nucleotide sequences that may serve e.g. as PCR primer sites or as target for hybridization to e.g. nucleic acid or PNA or LNA probes allowing affinity purification of cassettes.

20

25

The cassette may also optionally comprise another spacer sequence of at least two nucleotides between TR and RS2. When cassettes are cut out from a vector and concatenated into concatemers of cassettes, the spacer sequences together ensure that there is a certain distance between two successive identical promoter and/or terminator sequences. This distance may comprise at least 50 bases, such as at least 60 bases, for example at least 75 bases, such as at least 100 bases, for example at least 150 bases, such as at least 200 bases, for example at least 250

30

35

bases, such as at least 300 bases, for example at least 400 bases, for example at least 500 bases, such as at least 750 bases, for example at least 1000 bases, such as at least 1100 bases, for example at least 1200 bases, such as at least 1300 bases, for example at least 1400 bases, such as at least 1500 bases, for example at least 1600 bases, such as at least 1700 bases, for example at least 1800 bases, such as at least 1900 bases, for example at least 2000 bases, such as at least 2100 bases, for example at least 2200 bases, such as at least 2300 bases, for example at least 2400 bases, such as at least 2500 bases, for example at least 2600 bases, such as at least 2700 bases, for example at least 2800 bases, such as at least 2900 bases, for example at least 3000 bases, such as at least 3200 bases, for example at least 3500 bases, such as at least 3800 bases, for example at least 4000 bases, such as at least 4500 bases, for example at least 5000 bases, such as at least 6000 bases.

The number of the nucleotides between the spacer located 5' to the PR sequence and the one located 3' to the TR sequence may be any. However, it may be advantageous to ensure that at least one of the spacer sequences comprises between 100 and 2500 bases, preferably between 200 and 2300 bases, more preferably between 300 and 2100 bases, such as between 400 and 1900 bases, more preferably between 500 and 1700 bases, such as between 600 and 1500 bases, more preferably between 700 and 1400 bases.

If the intended host cell is yeast, the spacers present in a concatemer should preferably comprise a combination of a few ARSes with varying lambda phage DNA fragments.

Preferred examples of spacer sequences include but are not limited to: Lambda phage DNA, prokaryotic genomic DNA such as E. coli genomic DNA, ARSes.

Promoter

A promoter is a DNA sequence to which RNA polymerase binds and initiates transcription. The promoter determines the polarity of the transcript by specifying which strand will be transcribed.

- Bacterial promoters normally consist of -35 and -10 (relative to the transcriptional start) consensus sequences which are bound by a specific sigma factor and RNA polymerase.
- Eukaryotic promoters are more complex. Most promoters utilized in expression vectors are transcribed by RNA polymerase II. General transcription factors (GTFs) first bind specific sequences near the transcriptional start and then recruit the binding of RNA polymerase II. In addition to these minimal promoter elements, small sequence elements are recognized specifically by modular DNA-binding / trans-activating proteins (e.g. AP-1, SP-1) which regulate the activity of a given promoter.
- Viral promoters may serve the same function as bacterial and eukaryotic promoters. Upon viral infection of their host, viral promoters direct transcription either by using host transcriptional machinery or by supplying virally encoded enzymes to substitute part of the host machinery. Viral promoters are recognised by the transcriptional machinery of a large number of host organisms and are therefore often used in cloning and expression vectors.

Promoters may furthermore comprise regulatory elements, which are DNA sequence elements which act in conjunction with promoters and bind either repressors (e.g., lacO/ LAC Iq repressor system in *E. coli*) or inducers (e.g., gal1 /GAL4 inducer system in yeast). In either case, transcription is virtually "shut off" until the promoter is derepressed or induced, at which point transcription is "turned-on". The choice of promoter in the cassette is primarily dependent on the host organism into which the cassette is intended to be inserted. An important requirement to this end is that the promoter should preferably be capable of functioning in the host cell, in which the expressible nucleotide sequence is to be expressed.

Preferably the promoter is an externally controllable promoter, such as an inducible promoter and/or a repressible promoter. The promoter may be either controllable (repressible/inducible) by chemicals such as the absence/presence of chemical inducers, e.g. metabolites, substrates, metals, hormones, sugars. The promoter may likewise be controllable by certain physical parameters such as temperature, pH,

redox status, growth stage, developmental stage, or the promoter may be inducible/repressible by a synthetic inducer/repressor such as the gal inducer.

5 In order to avoid unintentional interference with the gene regulation systems of the host cell, and in order to improve controllability of the co-ordinated gene expression the promoter is preferably a synthetic promoter. Suitable promoters are described in US 5,798,227, US 5,667,986. Principles for designing suitable synthetic eukaryotic promoters are disclosed in US 5,559,027, US 5,877,018 or US 6,072,050.

10 Synthetic inducible eukaryotic promoters for the regulation of transcription of a gene may achieve improved levels of protein expression and lower basal levels of gene expression. Such promoters preferably contain at least two different classes of regulatory elements, usually by modification of a native promoter containing one of the inducible elements by inserting the other of the inducible elements. For example,
15 additional metal responsive elements (IREs) and/or glucocorticoid responsive elements (GREs) may be provided to native promoters. Additionally, one or more constitutive elements may be functionally disabled to provide the lower basal levels of gene expression.

20 Preferred examples of promoters include but is not limited to those promoters being induced and/or repressed by any factor selected from the group comprising carbohydrates, e.g. galactose; low inorganic phosphate levels; temperature, e.g. low or high temperature shift; metals or metal ions, e.g. copper ions; hormones, e.g. dihydrotestosterone; deoxycorticosterone; heat shock (e.g. 39°C); methanol; redox-
25 status; growth stage, e.g. developmental stage; synthetic inducers, e.g. gal inducer. Examples of such promoters include ADH 1, PGK 1, GAP 491, TPI, PYK, ENO, PMA 1, PHO5, GAL 1, GAL 2, GAL 10, MET25, ADH2, MEL 1, CUP 1, HSE, AOX, MOX, SV40, CaMV, Opaque-2, GRE, ARE, PGK/ARE hybrid, CYC/GRE hybrid, TPI/ α 2 operator, AOX 1, MOX A.

30 More preferably, however the promoter is selected from hybrid promoters such as PGK/ARE hybrid, CYC/GRE hybrid or from synthetic promoters. Such promoters can be controlled without interfering too much with the regulation of native genes in the expression host.

35

Yeast promoters

In the following, examples of known yeast promoters that may be used in conjunction with the present invention are shown. The examples are by no way
5 limiting and only serve to indicate to the skilled practitioner how to select or design promoters that are useful according to the present invention.

Although numerous transcriptional promoters which are functional in yeasts have been described in the literature, only some of them have proved effective for the
10 production of polypeptides by the recombinant route. There may be mentioned in particular the promoters of the PGK genes (3-phosphoglycerate kinase, TDH genes encoding GAPDH (Glyceraldehyde phosphate dehydrogenase), TEF1 genes (Elongation factor 1), MF α 1 (α sex pheromone precursor) which are considered as strong constitutive promoters or alternatively the regulatable promoter CYC1 which is
15 repressed in the presence of glucose or PHO5 which can be regulated by thiamine. However, for reasons which are often unexplained, they do not always allow the effective expression of the genes which they control. In this context, it is always advantageous to be able to have new promoters in order to generate new effective host/vector systems. Furthermore, having a choice of effective promoters in a given
20 cell also makes it possible to envisage the production of multiple proteins in this same cell (for example several enzymes of the same metabolic chain) while avoiding the problems of recombination between homologous sequences.

In general, a promoter region is situated in the 5' region of the genes and comprises
25 all the elements allowing the transcription of a DNA fragment placed under their control, in particular:

- (1) a so-called minimal promoter region comprising the TATA box and the site of initiation of transcription, which determines the position of the site of initiation as well as the basal level of transcription. In *Saccharomyces cerevisiae*, the length
30 of the minimal promoter region is relatively variable. Indeed, the exact location of the TATA box varies from one gene to another and may be situated from -40 to -120 nucleotides upstream of the site of the initiation (Chen and Struhl, 1985, EMBO J., 4, 3273-3280)
- (2) sequences situated upstream of the TATA box (immediately upstream up to
35 several hundreds of nucleotides) which make it possible to ensure an effective

level of transcription either constitutively (relatively constant level of transcription all along the cell cycle, regardless of the conditions of culture) or in a regulatable manner (activation of transcription in the presence of an activator and/or repression in the presence of a repressor). These sequences, may be of several types: activator, inhibitor, enhancer, inducer, repressor and may respond to cellular factors or varied culture conditions.

Examples of such promoters are the ZZA1 and ZZA2 promoters disclosed in US 5,641,661, the EF1- α protein promoter and the ribosomal protein S7 gene promoter disclosed in WO 97/44470,, the COX 4 promoter and two unknown promoters (SEQ ID No: 1 and 2 in the document) disclosed in US 5,952,195. Other useful promoters include the HSP150 promoter disclosed in WO 98/54339 and the SV40 and RSV promoters disclosed in US 4,870,013 as well as the PyK and GAPDH promoters disclosed in EP 0 329 203 A1.

Synthetic yeast promoters

More preferably the invention employs the use of synthetic promoters. Synthetic promoters are often constructed by combining the minimal promoter region of one gene with the upstream regulating sequences of another gene. Enhanced promoter control may be obtained by modifying specific sequences in the upstream regulating sequences, e.g. through substitution or deletion or through inserting multiple copies of specific regulating sequences. One advantage of using synthetic promoters is that they may be controlled without interfering too much with the native promoters of the host cell.

One such synthetic yeast promoter comprises promoters or promoter elements of two different yeast-derived genes, yeast killer toxin leader peptide, and amino terminus of IL-1 β (WO 98/54339).

Another example of a yeast synthetic promoter is disclosed in US 5,436,136 (Hinnen et al), which concerns a yeast hybrid promoter including a 5' upstream promoter element comprising upstream activation site(s) of the yeast PHO5 gene and a 3' downstream promoter element of the yeast GAPDH gene starting at nucleotide -300 to -180 and ending at nucleotide -1 of the GAPDH gene.

Another example of a yeast synthetic promoter is disclosed in US 5,089,398 (Rosenberg et al). This disclosure describes a promoter with the general formula - (P.R.(2)-P.R.(1))-

5 wherein:

P.R.(1) is the promoter region proximal to the coding sequence and having the transcription initiation site, the RNA polymerase binding site, and including the TATA box, the CAAT sequence, as well as translational regulatory signals, e.g., capping sequence, as appropriate;

10 P.R.(2) is the promoter region joined to the 5'-end of P.R.(1) associated with enhancing the efficiency of transcription of the RNA polymerase binding region;

In US 4,945,046 (Horii et al) discloses a further example of how to design a synthetic yeast promoter. This specific promoter comprises promoter elements
15 derived both from yeast and from a mammal. The hybrid promoter consists essentially of *Saccharomyces cerevisiae* PHO5 or GAP-DH promoter from which the upstream activation site (UAS) has been deleted and replaced by the early enhancer region derived from SV40 virus.

20 Cloning site

The cloning site in the cassette in the primary vector should be designed so that any nucleotide sequence can be cloned into it.

25 The cloning site in the cassette preferably allows directional cloning. Hereby is ensured that transcription in a host cell is performed from the coding strand in the intended direction and that the translated peptide is identical to the peptide for which the original nucleotide sequence codes.

30 However according to some embodiments it may be advantageous to insert the sequence in opposite direction. According to these embodiments, so-called antisense constructs may be inserted which prevent functional expression of specific genes involved in specific pathways. Thereby it may become possible to divert metabolic intermediates from a prevalent pathway to another less dominant
35 pathway.

5 The cloning site in the cassette may comprise multiple cloning sites, generally known as MCS or polylinker sites, which is a synthetic DNA sequence encoding a series of restriction endonuclease recognition sites. These sites are engineered for convenient cloning of DNA into a vector at a specific position and for directional cloning of the insert.

Cloning of cDNA does not have to involve the use of restriction enzymes. Other alternative systems include but are not limited to:

- 10
- Creator™ Cre-loxP system from Clontech, which uses recombination and loxP sites
 - use of Lambda attachment sites (att-λ), such as the Gateway™ system from Life Technologies.

Both of these systems are directional.

15

Terminator

20 The role of the terminator sequence is to limit transcription to the length of the coding sequence. An optimal terminator sequence is thus one, which is capable of performing this act in the host cell.

In prokaryotes, sequences known as transcriptional terminators signal the RNA polymerase to release the DNA template and stop transcription of the nascent RNA.

25 In eukaryotes, RNA molecules are transcribed well beyond the end of the mature mRNA molecule. New transcripts are enzymatically cleaved and modified by the addition of a long sequence of adenylic acid residues known as the poly-A tail. A polyadenylation consensus sequence is located about 10 to 30 bases upstream from the actual cleavage site.

30

Preferred examples of yeast derived terminator sequences include, but are not limited to: ADN1, CYC1, GPD, ADH1 alcohol dehydrogenase.

35

Intron

Optionally, the cassette in the vector comprises an intron sequence, which may be located 5' or 3' to the expressible nucleotide sequence. The design and layout of introns is well known in the art. The choice of intron design largely depends on the intended host cell, in which the expressible nucleotide sequence is eventually to be expressed. The effects of having intron sequence in the expression cassettes are those generally associated with intron sequences.

Examples of yeast introns can be found in the literature and in specific databases such as Ares Lab Yeast Intron Database (Version 2.1) as updated on 15 April 2000. Earlier versions of the database as well as extracts of the database have been published in: "Genome-wide bioinformatic and molecular analysis of introns in *Saccharomyces cerevisiae*." by Spingola M, Grate L, Haussler D, Ares M Jr. (RNA 1999 Feb;5(2):221-34) and "Test of intron predictions reveals novel splice sites, alternatively spliced mRNAs and new introns in meiotically regulated genes of yeast." by Davis CA, Grate L, Spingola M, Ares M Jr, (Nucleic Acids Res 2000 Apr 15;28(8):1700-6).

Primary vectors (entry vectors)

By the term entry vector is meant a vector for storing and amplifying cDNA or other expressible nucleotide sequences using the cassettes according to the present invention. The primary vectors are preferably able to propagate in *E. coli* or any other suitable standard host cell. It should preferably be amplifiable and amenable to standard normalisation and enrichment procedures.

The primary vector may be of any type of DNA that has the basic requirements of a) being able to replicate itself in at least one suitable host organism and b) allows insertion of foreign DNA which is then replicated together with the vector and c) preferably allows selection of vector molecules that contain insertions of said foreign DNA. In a preferred embodiment the vector is able to replicate in standard hosts like yeasts, and bacteria and it should preferably have a high copy number per host cell. It is also preferred that the vector in addition to a host specific origin of replication, contains an origin of replication for a single stranded virus, such as e.g. the f1 origin

for filamentous phages. This will allow the production of single stranded nucleic acid which may be useful for normalisation and enrichment procedures of cloned sequences. A vast number of cloning vectors have been described which are commonly used and references may be given to e.g. Sambrook, J; Fritsch, E.F; and Maniatis T. (1989) Molecular Cloning: A laboratory manual. Cold Spring Harbour Laboratory Press, USA, Netherlands Culture Collection of Bacteria (www.cbs.knaw.nl/NCCB/collection.htm) or Department of Microbial Genetics, National Institute of Genetics, Yata 1111 Mishima Shizuoka 411-8540, Japan (www.shigen.nig.ac.jp/cvector/cvector.html). A few type-examples that are the parents of many popular derivatives are M13mp10, pUC18, Lambda gt 10, and pYAC4. Examples of primary vectors include but are not limited to M13K07, pBR322, pUC18, pUC19, pUC118, pUC119, pSP64, pSP65, pGEM-3, pGEM-3Z, pGEM-3Zf(-), pGEM-4, pGEM-4Z, π AN13, pBluescript II, CHARON 4A, λ^+ , CHARON 21A, CHARON 32, CHARON 33, CHARON 34, CHARON 35, CHARON 40, EMBL3A, λ 2001, λ DASH, λ FIX, λ gt10, λ gt11, λ gt18, λ gt20, λ gt22, λ ORF8, λ ZAP/R, pJB8, c2RB, pcos1EMBL

Methods for cloning of cDNA or genomic DNA into a vector are well known in the art. Reference may be given to J. Sambrook, E.F. Fritsch, T. Maniatis: Molecular Cloning, A Laboratory Manual (2nd edition, Cold Spring Harbor Laboratory Press, 1989).

One example of a circular model entry vector is described in Figure 3. The vector, EVE contains the expression cassette, R1-R2-Spacer-Promoter-Multi Cloning Site-Terminator-Spacer-R2-R1. The vector furthermore contains a gene for ampicillin resistance, AmpR, and an origin of replication for E.coli, ColE1.

The entry vectors EVE4, EVE5, and EVE8 shown in Figures 4, 5, and 6. These all contain SrfI as R1 and Ascl as R2. Both of these sites are palindromic and are regarded as rare restriction sites having 8 bases in the recognition sequence. The vectors furthermore contain the AmpR ampicillin resistance gene, and the ColE1 origin or replication for E.coli as well as f1, which is an origin of replication for filamentous phages, such as M13. EVE4 (Fig. 4) contains the MET25 promoter and the ADH1 terminator. Spacer 1 and spacer 2 are short sequences deriving from the multiple cloning site, MCS. EVE5 (Fig. 5) contains the CUP1 promoter and the

ADH1 terminator. EVE8 (Fig. 6) contains the CUP1 promoter and the ADH1 terminator. The spacers of EVE8 are a 550 bp lambda phage DNA (spacer 3) and an ARS sequence from yeast (spacer 4).

5 **Nucleotide library (entry library)**

Methods as well as suitable vectors and host cells for constructing and maintaining a library of nucleotide sequences in a cell are well known in the art. The primary requirement for the library is that it should be possible to store and amplify in it a
10 number of primary vectors (constructs) according to this invention, the vectors (constructs) comprising expressible nucleotide sequences from at least one expression state and wherein at least two vectors (constructs) are different.

One specific example of such a library is the well known and widely employed cDNA
15 libraries. The advantage of the cDNA library is mainly that it contains only DNA sequences corresponding to transcribed messenger RNA in a cell. Suitable methods are also present to purify the isolated mRNA or the synthesised cDNA so that only substantially full-length cDNA is cloned into the library.

20 Methods for optimisation of the process to yield substantially full length cDNA may comprise size selection, e.g. electrophoresis, chromatography, precipitation or may comprise ways of increasing the likelihood of getting full length cDNAs, e.g. the SMART™ method (Clontech) or the CapTrap™ method (Stratagene).

25 Preferably the method for making the nucleotide library comprises obtaining a substantially full length cDNA population comprising a normalised representation of cDNA species. More preferably a substantially full length cDNA population comprises a normalised representation of cDNA species characteristic of a given expression state.

30 Normalisation reduces the redundancy of clones representing abundant mRNA species and increases the relative representation of clones from rare mRNA species.

Methods for normalisation of cDNA libraries are well known in the art. Reference may be given to suitable protocols for normalisation such as those described in US 5,763,239 (DIVERSA) and WO 95/08647 and WO 95/11986. and Bonaldo, Lennon, Soares, Genome Research 1996, 6:791-806; Ali, Holloway, Taylor, Plant Mol Biol Reporter, 2000, 18:123-132.

Enrichment methods are used to isolate clones representing mRNA which are characteristic of a particular expression state. A number of variations of the method broadly termed as subtractive hybridisation are known in the art. Reference may be given to Sive, John, Nucleic Acid Res, 1988, 16:10937; Diatchenko, Lau, Campbell et al, PNAS, 1996, 93:6025-6030; Carninci, Shibata, Hayatsu, Genome Res, 2000, 10:1617-30; Bonaldo, Lennon, Soares, Genome Research 1996, 6:791-806; Ali, Holloway, Taylor, Plant Mol Biol Reporter, 2000, 18:123-132. For example, enrichment may be achieved by doing additional rounds of hybridization similar to normalization procedures, using e.g. cDNA from a library of abundant clones or simply a library representing the uninduced state as a driver against a tester library from the induced state. Alternatively mRNA or PCR amplified cDNA derived from the expression state of choice can be used to subtract common sequences from a tester library. The choice of driver and tester population will depend on the nature of target expressible nucleotide sequences in each particular experiment.

In the library an expressible nucleotide sequence coding for one peptide is preferably found in different but similar vectors under the control of different promoters. Preferably the library comprises at least three primary vectors with an expressible nucleotide sequence coding for the same peptide under the control of three different promoters. More preferably the library comprises at least four primary vectors with an expressible nucleotide sequence coding for the same peptide under the control of four different promoters. More preferably the library comprises at least five primary vectors with an expressible nucleotide sequence coding for the same peptide under the control of five different promoters, such as comprises at least six primary vectors with an expressible nucleotide sequence coding for the same peptide under the control of six different promoters, for example comprises at least seven primary vectors with an expressible nucleotide sequence coding for the same peptide under the control of seven different promoters, for example comprises at least eight primary vectors with an expressible nucleotide sequence coding for the

same peptide under the control of eight different promoters, such as comprises at least nine primary vectors with an expressible nucleotide sequence coding for the same peptide under the control of nine different promoters, for example comprises at least ten primary vectors with an expressible nucleotide sequence coding for the same peptide under the control of ten different promoters.

The expressible nucleotide sequence coding for the same peptide preferably comprises essentially the same nucleotide sequence, more preferably the same nucleotide sequence.

By having a library with what may be termed one gene under the control of a number of different promoters in different vectors, it is possible to construct from the nucleotide library an array of combinations of genes and promoters. Preferably, one library comprises a complete or substantially complete combination such as a two dimensional array of genes and promoters, wherein substantially all genes are found under the control of substantially all of a selected number of promoters.

According to another embodiment of the invention the nucleotide library comprises combinations of expressible nucleotide sequences combined in different vectors with different spacer sequences and/or different intron sequences. Thus any one expressible nucleotide sequence may be combined in a two, three, four or five dimensional array with different promoters and/or different spacers and/or different introns and/or different terminators. The two, three, four or five dimensional array may be complete or incomplete, since not all combinations will have to be present.

The library may suitably be maintained in a host cell comprising prokaryotic cells or eukaryotic cells. Preferred prokaryotic host organisms may include but are not limited to *Escherichia coli*, *Bacillus subtilis*, *Streptomyces lividans*, *Streptomyces coelicolor*, *Pseudomonas aeruginosa*, *Myxococcus xanthus*.

Yeast species such as *Saccharomyces cerevisiae* (budding yeast), *Schizosaccharomyces pombe* (fission yeast), *Pichia pastoris*, and *Hansenula polymorpha* (methylotropic yeasts) may also be used. Filamentous ascomycetes, such as *Neurospora crassa* and *Aspergillus nidulans* may also be used. Plant cells such as those derived from *Nicotiana* and *Arabidopsis* are preferred. Preferred

mammalian host cells include but are not limited to those derived from humans, monkeys and rodents, such as chinese hamster ovary (CHO) cells, NIH/3T3, COS, 293, VERO, HeLa etc (see Kriegler M. in "Gene Transfer and Expression: A Laboratory Manual", New York, Freeman & Co. 1990).

5

Concatemers

A concatemer is a series of linked units. In the present context a concatemer is used to denote a number of serially linked nucleotide cassettes, wherein at least two of the serially linked nucleotide units comprises a cassette having the basic structure

10

[rs₂-SP-PR-X-TR-SP-rs₁]

wherein

rs₁ and rs₂ together denote a restriction site,

SP individually denotes a spacer of at least two nucleotide bases,

15

PR denotes a promoter, capable of functioning in a cell,

X denotes an expressible nucleotide sequence,

TR denotes a terminator, and

SP individually denotes a spacer of at least two nucleotide bases.

20

Optionally the cassettes comprise an intron sequence between the promoter and the expressible nucleotide sequence and/or between the terminator and the expressible sequence.

25

The expressible nucleotide sequence in the cassettes of the concatemer may comprise a DNA sequence selected from the group comprising cDNA and genomic DNA.

30

According to one aspect of the invention, a concatemer comprises cassettes with expressible nucleotide from different expression states, so that non-naturally occurring combinations or non-native combinations of expressible nucleotide sequences are obtained. These different expression states may represent at least two different tissues, such as at least two organs, such as at least two species, such as at least two genera. The different species may be from at least two different phylae, such as from at least two different classes, such as from at least two

different divisions, more preferably from at least two different sub-kingdoms, such as from at least two different kingdoms.

For example, the expressible nucleotide sequences may originate from eukaryots such as mammals such as humans, mice or whale, from reptiles such as snakes crocodiles or turtles, from tunicates such as sea squirts, from lepidoptera such as butterflies and moths, from coelenterates such as jellyfish, anenomes, or corals, from fish such as bony and cartilaginous fish, from plants such as dicots, e.g. coffee, oak or monocots such as grasses, lilies, and orchids; from lower plants such as algae and ginkgo, from higher fungi such as terrestrial fruiting fungi, from marine actinomycetes. The expressible nucleotide sequences may also originate from protozoans such as malaria or trypanosomes, or from prokaryotes such as *E. coli* or archaeobacteria. Furthermore, the expressible nucleotide sequences may originate from one or more preferably from more expression states from the species and genera listed in the table below.

20	Bacteria	Streptomyces, Micromonospora, Norcadia, Actinomadura, Actinoplanes, Streptosporangium, Microbispora, Kitasatosporium, Azobacterium, Rhizobium, Achromobacterium, Enterobacterium, Brucella, Micrococcus, Lactobacillus, Bacillus (B.t. toxins), Clostridium (toxins), Brevibacterium, Pseudomonas, Aerobacter, Vibrio, Halobacterium, Mycoplasma, Cytophaga, Myxococcus
25	Fungi	Amanita muscaria (fly agaric, ibotenic acid, muscimol), Psilocybe (psilocybin) Physarium, Fuligo, Mucor, Phytophthora, Rhizopus, Aspergillus, Penicillium (penicillin), Coprinus, Phanerochaete, Acremonium (Cephalosporin), Trochoderma, Helminthosporium, Fusarium, Alternaria, Myrothecium, Saccharomyces
30	Algae	Digenea simplex (kainic acid, antihelminthic), Laminaria anqustata (laminine, hypotensive)
	Lichens	Usnea fasciata (vulpinicacid, antimicrobial; usnic acid, antitumor)
35	Higher Plants	Artemisia (artemisinin), Coleus (forskolin), Desmodium (K channel agonist), Catharanthus (Vinca alkaloids), Digitalis (cardiac glycosides), Podophyllum (podophyllotoxin), Taxus (taxol), Cephalotaxus (homoharringtonine), Camptotheca (Camptothecin), Camellia sinensis (Tea), Cannabis indica, Cannabis sativa (Hemp), Erythroxylum coca (Coca), Lophophora williamsii (Peyote), Myristica fragrans

		(Nutmeg), <i>Nicotiana</i> , <i>Papaver somniferum</i> (Opium Poppy), <i>Phalaris arundinacea</i> (Reed canary grass)
5	Protozoa	<i>Ptychodiscus brevis</i> ; Dinoflagellates (brevitoxin, cardiovascular)
	Sponges	<i>Microciona prolifera</i> (ectyonin, antimicrobial) <i>Cryptotethya crypta</i> (D-arabino furanosides)
10	Coelenterata	Portuguese Man o War & other jellyfish and medusoid toxins.
	Corals	<i>Pseudoterogonia</i> species (Pseudoteracins, anti-inflammatory), <i>Erythropodium</i> (erythrolides, anti-inflammatory)
15	Aschelminths	Nematode secretory compounds
	Molluscs	<i>Conus</i> toxins, sea slug toxins, cephalopod neurotransmitters, squid inks
	Annelida	<i>Lumbriconereis heteropa</i> (nereistoxin, insecticidal)
20	Arachnids	<i>Dolomedes</i> ("fishing spider" venoms)
	Crustacea	<i>Xenobalanus</i> (skin adhesives)
25	Insects	<i>Epilachna</i> (mexican bean beetle alkaloids)
	Spinunculida	<i>Bonellia viridis</i> (bonellin, neuroactive)
	Bryozoans	<i>Bugula neritina</i> (bryostatins, anti cancer)
30	Echinoderms	Crinoid chemistry
	Tunicates	<i>Trididemnum solidum</i> (didemnins, anti-tumor and anti-viral; <i>Ecteinascidia turbinata</i> ecteinascidins, anti-tumor)
35	Vertebrates	<i>Eptatretus stoutii</i> (eptatretin, cardioactive), <i>Trachinus draco</i> (proteinaceous toxins, reduce blood pressure, respiration and reduce heart rate). Dendrobatid frogs (batrachotoxins, pumiliotoxins, histrionicotoxins, and other polyamines); Snake venom toxins; <i>Ornithorhynchus anatinus</i> (duck-billed platypus venom), modified carotenoids, retinoids and steroids; Avians: histrionicotoxins, modified carotenoids, retinoids and steroids
40		

According to a preferred embodiment of the invention the concatemer comprises at least a first cassette and a second cassette, said first cassette being different from

said second cassette. More preferably, the concatemer comprises cassettes, wherein substantially all cassettes are different. The difference between the cassettes may arise from differences between promoters, and/or expressible nucleotide sequences, and/or spacers, and/or terminators, and/or introns.

5

The number of cassettes in a single concatemer is largely determined by the host species into which the concatemer is eventually to be inserted and the vector through which the insertion is carried out. The concatemer thus may comprise at least 10 cassettes, such as at least 15, for example at least 20, such as at least 25, 10 for example at least 30, such as from 30 to 60 or more than 60, such as at least 75, for example at least 100, such as at least 200, for example at least 500, such as at least 750, for example at least 1000, such as at least 1500, for example at least 2000 cassettes.

15

Each of the cassettes may be laid out as described above.

20

Once the concatemer has been assembled or concatenated it may be ligated into a suitable vector. Such a vector may advantageously comprise an artificial chromosome. The basic requirements for a functional artificial chromosome have been described in US 4,464,472, the contents of which is hereby incorporated by reference. An artificial chromosome or a functional minichromosome, as it may also be termed must comprise a DNA sequence capable of replication and stable mitotic maintenance in a host cell comprising a DNA segment coding for centromere-like activity during mitosis of said host and a DNA sequence coding for a replication site 25 recognized by said host.

30

Suitable artificial chromosomes include a Yeast Artificial Chromosome (YAC) (see e.g. Murray et al, Nature 305:189-193; or US 4,464,472), a mega Yeast Artificial Chromosome (mega YAC), a Bacterial Artificial Chromosome (BAC), a mouse artificial chromosome, a Mammalian Artificial Chromosome (MAC) (see e.g. US 6,133,503 or US 6,077,697), an Insect Artificial Chromosome (BUGAC), an Avian Artificial Chromosome (AVAC), a Bacteriophage Artificial Chromosome, a Baculovirus Artificial Chromosome, a plant artificial chromosome (US 5,270,201), a BIBAC vector (US 5,977,439) or a Human Artificial Chromosome (HAC).

35

The artificial chromosome is preferably so large that the host cell perceives it as a "real" chromosome and maintains it and transmits it as a chromosome. For yeast and other suitable host species, this will often correspond approximately to the size of the smallest native chromosome in the species. For *Saccharomyces*, the smallest chromosome has a size of 225 Kb.

MACs may be used to construct artificial chromosomes from other species, such as insect and fish species. The artificial chromosomes preferably are fully functional stable chromosomes. Two types of artificial chromosomes may be used. One type, referred to as SATACs [satellite artificial chromosomes] are stable heterochromatic chromosomes, and the other type are minichromosomes based on amplification of euchromatin.

Mammalian artificial chromosomes provide extra-genomic specific integration sites for introduction of genes encoding proteins of interest and permit megabase size DNA integration, such as integration of concatemers according to the invention.

According to another embodiment of the invention, the concatemer may be integrated into the host chromosomes or cloned into other types of vectors, such as a plasmid vector, a phage vector, a viral vector or a cosmid vector.

A preferable artificial chromosome vector is one that is capable of being conditionally amplified in the host cell, e.g. in yeast. The amplification preferably is at least a 10 fold amplification. Furthermore, it is advantageous that the cloning site of the artificial chromosome vector can be modified to comprise the same restriction site as the one bordering the cassettes described above, i.e. RS2 and/or RS2'.

Concatenation

Cassettes to be concatenated are normally excised from a vector either by digestion with restriction enzymes or by PCR. After excision the cassettes may be separated from the vector through size fractionation such as gel filtration or through tagging of known sequences in the cassettes. The isolated cassettes may then be joined together either through interaction between sticky ends or through ligation of blunt ends.

Single-stranded compatible ends may be created by digestion with restriction enzymes. For concatenation a preferred enzyme for excising the cassettes would be a rare cutter, i.e. an enzyme that recognises a sequence of 7 or more nucleotides. Examples of enzymes that cut very rarely are the meganucleases, many of which are intron encoded, like e.g. I-Ceu I, I-Sce I, I-Ppo I, and PI-Psp I (see example 6d for more). Other preferred enzymes recognize a sequence of 8 nucleotides like e.g. Asc I, AsiS I, CciN I, CspB I, Fse I, MchA I, Not I, Pac I, Sbf I, Sda I, Sgf I, SgrA I, Sse232 I, and Sse8387 I, all of which create single stranded, palindromic compatible ends.

Other preferred rare cutters, which may also be used to control orientation of individual cassettes in the concatemer are enzymes that recognize non-palindromic sequences like e.g. Aar I, Sap I, Sfi I, Sdi I, and Vpa (see example 6c for more).

Alternatively, cassettes can be prepared by the addition of restriction sites to the ends, e.g. by PCR or ligation to linkers (short synthetic dsDNA molecules). Restriction enzymes are continuously being isolated and characterised and it is anticipated that many of such novel enzymes can be used to generate single-stranded compatible ends according to the present invention.

It is conceivable that single stranded compatible ends can be made by cleaving the vector with synthetic cutters. Thus, a reactive chemical group that will normally be able to cleave DNA unspecifically can cut at specific positions when coupled to another molecule that recognises and binds to specific sequences. Examples of molecules that recognise specific dsDNA sequences are DNA, PNA, LNA, phosphothioates, peptides, and amides. See e.g. Armitage, B. (1998) Chem. Rev. 98: 1171-1200, who describes photocleavage using e.g. anthraquinone and UV light; Dervan P.B. & Bürli R.W. (1999) Curr. Opin. Chem. Biol. 3: 688-93 describes the specific binding of polyamides to DNA; Nielsen, P.E. (2001) Curr. Opin. Biotechnol. 12: 16-20 describes the specific binding of PNA to DNA, and Chemical Reviews special thematic issue: RNA/DNA Cleavage (1998) vol. 98 (3) Bashkin J.K. (ed.) ACS publications, describes several examples of chemical DNA cleavers.

Single-stranded compatible ends may also be created by using e.g. PCR primers including dUTP and then treating the PCR product with Uracil-DNA glycosylase (Ref: US 5,035,996) to degrade part of the primer. Alternatively, compatible ends can be created by tailing both the vector and insert with complimentary nucleotides using Terminal Transferase (Chang, LMS, Bollum TJ (1971) J Biol Chem 246:909).

It is also conceivable that recombination can be used to generate concatemers, e.g. through the modification of techniques like the Creator™ system (Clontech) which uses the Cre-loxP mechanism (Sauer B 1993 Methods Enzymol 225:890-900) to directionally join DNA molecules by recombination or like the Gateway™ system (Life Technologies, US 5,888,732) using lambda *att* attachment sites for directional recombination (Landy A 1989, Ann Rev Biochem 58:913). It is envisaged that also lambda *cos* site dependent systems can be developed to allow concatenation.

More preferably the cassettes may be concatenated without an intervening purification step through excision from a vector with two restriction enzymes, one leaving sticky ends on the cassettes and the other one leaving blunt ends in the vectors. This is the preferred method for concatenation of cassettes from vectors having the basic structure of [RS1-RS2-SP-PR-X-TR-SP-RS2'-RS1'].

An alternative way of producing concatemers free of vector sequences would be to PCR amplify the cassettes from a single-stranded primary vector. The PCR product must include the restriction sites RS2 and RS2' which are subsequently cleaved by its cognate enzyme(s). Concatenation can then be performed using the digested PCR product, essentially without interference from the single stranded primary vector template or the small double stranded fragments, which have been cut from the ends.

The concatemer may be assembled or concatenated by concatenation of at least two cassettes of nucleotide sequences each cassette comprising a first sticky end, a spacer sequence, a promoter, an expressible nucleotide sequence, a terminator, a spacer sequence, and a second sticky end. A flow chart of the procedure is shown in figure 2a.

Preferably concatenation further comprises

starting from a primary vector [RS1-RS2-SP-PR-X-TR-SP-RS2'-RS1'],

wherein X denotes an expressible nucleotide sequence,

RS1 and RS1' denote restriction sites,

5 RS2 and RS2' denote restriction sites different from RS1 and RS1',

SP individually denotes a spacer sequence of at least two nucleotides,

PR denotes a promoter,

TR denotes a terminator,

- 10 i) cutting the primary vector with the aid of at least one restriction enzyme specific for RS2 and RS2' obtaining cassettes having the general formula [rs₂-SP-PR-X-TR-SP-rs₁] wherein rs₁ and rs₂ together denote a functional restriction site RS2 or RS2',
- ii) assembling the cut out cassettes through interaction between rs₁ and rs₂.

15

In this way at least 10 cassettes can be concatenated, such as at least 15, for example at least 20, such as at least 25, for example at least 30, such as from 30 to 60 or more than 60, such as at least 75, for example at least 100, such as at least 200, for example at least 500, such as at least 750, for example at least 1000; such as at least 1500, for example at least 2000.

20

According to an especially preferred embodiment, vector arms each having a RS2 or RS2' in one end and a non-complementary overhang or a blunt end in the other end are added to the concatenation mixture together with the cassettes described above to further simplify the procedure (see Fig. 2b). One example of a suitable vector for providing vector arms is disclosed in Fig. 7 TRP1, URA3, and HIS3 are auxotrophic marker genes, and AmpR is an E. coli antibiotic marker gene. CEN4 is a centromer and TEL are telomeres. ARS1 and PMB1 allow replication in yeast and E. coli respectively. BamH I and Asc I are restriction enzyme recognition sites. The nucleotide sequence of the vector is set forth in SEQ ID NO 4. The vector is digested with BamHI and AscI to liberate the vector arms, which are used for ligation to the concatemer.

25

30

The ratio of vector arms to cassettes determines the maximum number of cassettes in the concatemer as illustrated in figure 8. The vector arms preferably are artificial chromosome vector arms such as those described in Fig. 7.

5 It is of course also possible to add stopper fragments to the concatenation solution, the stopper fragments each having a RS2 or RS2' in one end and a non-complementary overhang or a blunt end in the other end. The ratio of stopper fragments to cassettes can likewise control the maximum size of the concatemer.

10 The complete sequence of steps to be taken when starting with the isolation of mRNA until inserting into an entry vector may include the following steps

- i) isolating mRNA from an expression state,
- ii) obtaining substantially full length cDNA corresponding to the mRNA sequences,
- 15 iii) inserting the substantially full length cDNA into a cloning site in a cassette in a primary vector, said cassette being of the general formula in 5'→3' direction:
[RS1-RS2-SP-PR-CS-TR-SP-RS2'-RS1']
wherein CS denotes a cloning site.

20

In preparation of the concatemer, genes may be isolated from different entry libraries to provide the desired selection of genes. Accordingly, concatenation may further comprise selection of vectors having expressible nucleotide sequences from at least two different expression states, such as from two different species. The two
25 different species may be from two different classes, such as from two different divisions, more preferably from two different sub-kingdoms, such as from two different kingdoms.

30 As an alternative to including vector arms in the concatenation reaction it is possible to ligate the concatemer into an artificial chromosome selected from the group comprising yeast artificial chromosome, mega yeast artificial chromosome, bacterial artificial chromosome, mouse artificial chromosome, human artificial chromosome.

Preferably at least one inserted concatemer further comprises a selectable marker.
35 The marker(s) are conveniently not included in the concatemer as such but rather in

an artificial chromosome vector, into which the concatemer is inserted. Selectable markers generally provide a means to select, for growth, only those cells which contain a vector. Such markers are of two types: drug resistance and auxotrophy. A drug resistance marker enables cells to grow in the presence of an otherwise toxic compound. Auxotrophic markers allow cells to grow in media lacking an essential component by enabling cells to synthesise the essential component (usually an amino acid).

Illustrative and non-limiting examples of common compounds for which selectable markers are available with a brief description of their mode of action follow:

Prokaryotic

- Ampicillin: interferes with a terminal reaction in bacterial cell wall synthesis. The resistance gene (bla) encodes beta-lactamase which cleaves the beta-lactam ring of the antibiotic thus detoxifying it.
- Tetracycline: prevents bacterial protein synthesis by binding to the 30S ribosomal subunit. The resistance gene (tet) specifies a protein that modifies the bacterial membrane and prevents accumulation of the antibiotic in the cell.
- Kanamycin: binds to the 70S ribosomes and causes misreading of messenger RNA. The resistant gene (nptII) modifies the antibiotic and prevents interaction with the ribosome.
- Streptomycin: binds to the 30S ribosomal subunit, causing misreading of messenger RNA. The resistance gene (Sm) modifies the antibiotic and prevents interaction with the ribosome.
- Zeocin: this new bleomycin-family antibiotic intercalates into the DNA and cleaves it. The Zeocin resistance gene encodes a 13,665 dalton protein. This protein confers resistance to Zeocin by binding to the antibiotic and preventing it from binding DNA. Zeocin is effective on most aerobic cells and can be used for selection in mammalian cell lines, yeast, and bacteria.

Eukaryotic

- Hygromycin: a aminocyclitol that inhibits protein synthesis by disrupting ribosome translocation and promoting mistranslation. The resistance gene (hph) detoxifies hygromycin -B- phosphorylation.

- Histidinol: cytotoxic to mammalian cells by inhibiting histidyl-tRNA synthesis in histidine free media. The resistance gene (*hisD*) product inactivates histidinol toxicity by converting it to the essential amino acid, histidine.
- Neomycin (G418): blocks protein synthesis by interfering with ribosomal functions. The resistance gene *ADH* encodes amino glycoside phosphotransferase which detoxifies G418.
- Uracil: Laboratory yeast strains carrying a mutated gene which encodes orotidine -5'- phosphate decarboxylase, an enzyme essential for uracil biosynthesis, are unable to grow in the absence of exogenous uracil. A copy of the wild-type gene (*ura4+*, *S. pombe* or *URA3 S. cerevisiae*) carried on the vector will complement this defect in transformed cells.
- Adenosine: Laboratory strains carrying a deficiency in adenosine synthesis may be complemented by a vector carrying the wild type gene, *ADE 2*.
- Amino acids: Vectors carrying the wild-type genes for *LEU2*, *TRP 1*, *HIS 3* or *LYS 2* may be used to complement strains of yeast deficient in these genes.
- Zeocin: this new bleomycin-family antibiotic intercalates into the DNA and cleaves it. The Zeocin resistance gene encodes a 13,665 dalton protein. This protein confers resistance to Zeocin by binding to the antibiotic and preventing it from binding DNA. Zeocin is effective on most aerobic cells and can be used for selection in mammalian cell lines, yeast, and bacteria.

Transgenic cells

In one aspect of the invention, the concatemers comprising the multitude of cassettes are introduced into a host cell, in which the concatemers can be maintained and the expressible nucleotide sequences can be expressed in a co-ordinated way. The cassettes comprised in the concatemers may be isolated from the host cell and re-assembled due to their uniform structure with –preferably – concatemer restriction sites between the cassettes.

The host cells selected for this purpose are preferably cultivable under standard laboratory conditions using standard culture conditions, such as standard media and protocols. Preferably the host cells comprise a substantially stable cell line, in which the concatemers can be maintained for generations of cell division. Standard

techniques for transformation of the host cells and in particular methods for insertion of artificial chromosomes into the host cells are known.

5 It is also of advantage if the host cells are capable of undergoing meiosis to perform sexual recombination. It is also advantageous that meiosis is controllable through external manipulations of the cell culture. One especially advantageous host cell type is one where the cells can be manipulated through external manipulations into different mating types.

10 The genome of a number of species have already been sequenced more or less completely and the sequences can be found in databases. The list of species for which the whole genome has been sequenced increases constantly. Preferably the host cell is selected from the group of species, for which the whole genome or essentially the whole genome has been sequenced. The host cell should preferably
15 be selected from a species that is well described in the literature with respect to genetics, metabolism, physiology such as model organism used for genomics research.

20 The host organism should preferably be conditionally deficient in the abilities to undergo homologous recombination. The host organism should preferably have a codon usage similar to that of the donor organisms. Furthermore, in the case of genomic DNA, if eukaryotic donor organisms are used, it is preferable that the host organism has the ability to process the donor messenger RNA properly, e.g., splice out introns.

25 The host cells can be bacterial, archaeobacteria, or eukaryotic and can constitute a homogeneous cell line or mixed culture. Suitable cells include the bacterial and eukaryotic cell lines commonly used in genetic engineering and protein expression.

30 Preferred prokaryotic host organisms may include but are not limited to *Escherichia coli*, *Bacillus subtilis*, *B. licheniformis*, *B. cereus*, *Streptomyces lividans*, *Streptomyces coelicolor*, *Pseudomonas aeruginosa*, *Myxococcus xanthus*, *Rhodococcus*, *Streptomyces*, *Actinomycetes*, *Corynebacteria*, *Bacillus*, *Pseudomonas*, *Salmonella*, and *Erwinia*. The complete genome sequences of *E.*

coli and *Bacillus subtilis* are described by Blattner et al., Science 277, 1454-1462 (1997); Kunst et al., Nature 390, 249-256 (1997)).

5 Preferred eukaryotic host organisms are mammals, fish, insects, plants, algae and fungi.

10 Examples of mammalian cells include those from, e.g., monkey, mouse, rat, hamster, primate, and human, both cell lines and primary cultures. Preferred mammalian host cells include but are not limited to those derived from humans, monkeys and rodents, such as chinese hamster ovary (CHO) cells, NIH/3T3, COS, 293, VERO, HeLa etc (see Kriegler M. in "Gene Transfer and Expression: A Laboratory Manual", New York, Freeman & Co. 1990), and stem cells, including embryonic stem cells and hemopoietic stem cells, zygotes, fibroblasts, lymphocytes, kidney, liver, muscle, and skin cells.

15

Examples of insect cells include baculo lepidoptera.

20 Examples of plant cells include maize, rice, wheat, cotton, soybean, and sugarcane. Plant cells such as those derived from *Nicotiana* and *Arabidopsis* are preferred

20

25 Examples of fungi include penicillium, aspergillus, such as *Aspergillus nidulans*, *podospora*, *neurospora*, such as *Neurospora crassa*, *saccharomyces*, such as *Saccharomyces cerevisiae* (budding yeast), *Schizosaccharomyces*, such as *Schizosaccharomyces pombe* (fission yeast), *Pichia* spp, such as *Pichia pastoris*, and *Hansenula polymorpha* (methylotropic yeasts).

30 In a preferred embodiment the host cell is a yeast cell, and an illustrative and not limiting list of suitable yeast host cells comprise: baker's yeast, *Kluyveromyces marxianus*, *K. lactis*, *Candida utilis*, *Phaffia rhodozyma*, *Saccharomyces boulardii*, *Pichia pastoris*, *Hansenula polymorpha*, *Yarrowia lipolytica*, *Candida paraffinica*, *Schwanniomyces castellii*, *Pichia stipitis*, *Candida shehatae*, *Rhodotorula glutinis*, *Lipomyces lipofer*, *Cryptococcus curvatus*, *Candida* spp. (e.g. *C. palmioleophila*), *Yarrowia lipolytica*, *Candida guilliermondii*, *Candida*, *Rhodotorula* spp., *Saccharomycopsis* spp., *Aureobasidium pullulans*, *Candida brumptii*, *Candida*
35 *hydrocarbofumarica*, *Torulopsis*, *Candida tropicalis*, *Saccharomyces cerevisiae*,

Rhodotorula rubra, Candida flaveri, Eremothecium ashbyii, Pichia spp., Pichia pastoris, Kluyveromyces, Hansenula, Kloeckera, Pichia, Pachysolen spp., or Torulopsis bombicola.

- 5 The choice of host will depend on a number of factors, depending on the intended use of the engineered host, including pathogenicity, substrate range, environmental hardness, presence of key intermediates, ease of genetic manipulation, and likelihood of promiscuous transfer of genetic information to other organisms. Particularly advantageous hosts are E. coli, lactobacilli, Streptomyces, 10 Actinomycetes, Saccharomyces and filamentous fungi.

In any one host cell it is possible to make all sorts of combinations of expressible nucleotide sequences from all possible sources. Furthermore, it is possible to make combinations of promoters and/or spacers and/or introns and/or terminators in 15 combination with one and the same expressible nucleotide sequence.

Thus in any one cell there may be expressible nucleotide sequences from two different expression states. Furthermore, these two different expression states may be from one species or advantageously from two different species. Any one host cell 20 may also comprise expressible nucleotide sequences from at least three species, such as from at least four, five, six, seven, eight, nine or ten species, or from more than 15 species such as from more than 20 species, for example from more than 30, 40 or 50 species, such as from more than 100 different species, for example from more than 300 different species, such as from more than 500 different species, for 25 example from more than 1000 different species, thereby obtaining combinations of large numbers of expressible nucleotide sequences from a large number of species. In this way potentially unlimited numbers of combinations of expressible nucleotide sequences can be combined across different expression states. These different expression states may represent at least two different tissues, such as at least two organs, such as at least two species, such as at least two genera. The different 30 species may be from at least two different phylae, such as from at least two different classes, such as from at least two different divisions, more preferably from at least two different sub-kingdoms, such as from at least two different kingdoms.

47

Any two of these species may be from two different classes, such as from two different divisions, more preferably from two different sub-kingdoms, such as from two different kingdoms. Thus expressible nucleotide sequences may be combined from a eukaryot and a prokaryot into one and the same cell.

5

According to another embodiment of the invention, the expressible nucleotide sequences may be from one and the same expression state. The products of these sequences may interact with the products of the genes in the host cell and form new enzyme combinations leading to novel biochemical pathways. Furthermore, by putting the expressible nucleotide sequences under the control of a number of promoters it becomes possible to switch on and off groups of genes in a co-ordinated manner. By doing this with expressible nucleotide sequences from only one expression states, novel combinations of genes are also expressed.

10

15

The number of concatemers in one single cell may be at least one concatemer per cell, preferably at least 2 concatemers per cell, more preferably 3 per cell, such as 4 per cell, more preferably 5 per cell, such as at least 5 per cell, for example at least 6 per cell, such as 7, 8, 9 or 10 per cell, for example more than 10 per cell. As described above, each concatemer may preferably comprise up to 1000 cassettes, and it is envisaged that one concatemer may comprise up to 2000 cassettes. By inserting up to 10 concatemers into one single cell, this cell may thus be enriched with up to 20,000 heterologous expressible genes, which under suitable conditions may be turned on and off by regulation of the regulatable promoters.

20

25

Often it is more preferable to provide cells having anywhere between 10 and 1000 heterologous genes, such as 20-900 heterologous genes, for example 30 to 800 heterologous genes, such as 40 to 700 heterologous genes, for example 50 to 600 heterologous genes, such as from 60 to 300 heterologous genes or from 100 to 400 heterologous genes which are inserted as 2 to 4 artificial chromosomes each containing one concatemer of genes. The genes may advantageously be located on 1 to 10 such as from 2 to 5 different concatemers in the cells. Each concatemer may advantageously comprise from 10 to 1000 genes, such as from 10 to 750 genes, such as from 10 to 500 genes, such as from 10 to 200 genes, such as from 20 to 100 genes, for example from 30 to 60 genes, or from 50 to 100 genes.

30

35

The concatemers may be inserted into the host cells according to any known transformation technique, preferably according to such transformation techniques that ensure stable and not transient transformation of the host cell. The concatemers may thus be inserted as an artificial chromosome which is replicated by the cells as they divide or they may be inserted into the chromosomes of the host cell. The concatemer may also be inserted in the form of a plasmid such as a plasmid vector, a phage vector, a viral vector, a cosmid vector, that is replicated by the cells as they divide. Any combination of the three insertion methods is also possible. One or more concatemers may thus be integrated into the chromosome(s) of the host cell and one or more concatemers may be inserted as plasmids or artificial chromosomes. One or more concatemers may be inserted as artificial chromosomes and one or more may be inserted into the same cell via a plasmid.

Examples

Example 1

In the examples 1-3 an Asc1 site was introduced into the EcoR1 site in pYAC4 (Sigma, Burke DT et al. 1987, Science vol 236, p 806), so that sticky ends match the Asc1 site(= RS2 in general formula of this patent) of the cassettes in pEVE vectors

Preparation of EVACs (EVolvable Artificial Chromosomes) including size fractioning

preparation of pYAC4-Asc arms

1. inoculate 150 ml of LB (sigma) with a single colony of E. coli DH5 α containing pYAC4-Asc
2. grow to OD600 ~ 1, harvest cells and make plasmid preparation
3. digest 100 μ g pYAC4-Asc w. BamH1 and Asc1
4. dephosphorylate fragments and heat inactivate phosphatase(20 min, 80 C)
5. purify fragments(e.g. Qiaquick Gel Extraction Kit)
6. run 1 % agarose gel to estimate amount of fragment

Preparation of expression cassettes

1. take 100 μ g of plasmid preparation from each of the following libraries
 - a) pMA-CAR

- b). pCA-CAR
- c) Phaffia cDNA library
- d) Carrot cDNA library
2. digest w. Srf1(10 units/prep, 37C overnight)
- 5 3. dephosphorylate (10 units/prep, 37C, 2h)
4. heat inactivate 80C, 20 min
5. concentrate and change buffer (precipitation or ultra filtration),
6. digest w. Asc1. (10 units/prep, 37 C, overnight)
7. adjust volume of preps to 100 μ L

10

preparation of EVACs

Different types of EVACs have been made by varying the ratio of the different libraries that goes into the ligation reaction.

	pMA-CAR	pCA-CAR	Phaffia cDNA	Carrot cDNA
EVAC				
A	<u>40%</u>	<u>40%</u>	<u>10%</u>	<u>10%</u>
B	<u>25%</u>	<u>25%</u>	<u>25%</u>	<u>25%</u>

15

1. add ~100 ng arms of pYAC4-Asc /100 μ g of cassette mixture
2. concentrate to < 33.5 μ L
3. add 2.5 units of T4 DNA-ligase + 4 μ L 10x ligase buffer. Adjust to 40 μ L
- 20 4. ligate 3 h, 16 C
5. stop reaction by adding 2 μ L of 500 mM EDTA
6. bring reaction volume to 125 μ L, add 25 μ L loading mix, heat at 60C for 5 min
7. distribute evenly in 10 wells of a 1% LMP agarose gel
- 25 8. run pulsed field gel (CHEF III, 1% LMP agarose, $\frac{1}{2}$ strength TBE (BioRad), angle 120, temperature 12 C, voltage 5.6V/cm, switch time ramping 5 – 25 s, run time 30 h)
9. stain part of the gel that contains molecular weight markers + 1 sample lane for quality check
- 30 10. cut remaining 9 sample lanes corresponding to mw. 97 – 194 kb(fraction 1); 194 – 291 kb(fraction 2); 291-365 kb(fraction 3) from the gel

50

11. agarose gel in high NaCl agarose buffer . 1 u agarase / 100µg gel. 40C 3 h
12. concentrate preparation to < 20 µL
13. transform suitable yeast strain w. preparation using alkali/cation transformation
- 5 14. plate on selective minimal media plates
15. incubate 30 C for 4-5 days
16. pick colonies
17. analyse colonies

10 Example 2

Preparation of EVACs (EVolvable Artificial Chromosomes) with direct transformation

preparation of pYAC4-Asc arms

1. inoculate 150 ml of LB with a single colony of DH5α containing pYAC4-Asc
- 15 2. grow to OD600 ~ 1, harvest cells and make plasmid preparation
3. digest 100µg pYAC4-Asc w. BamH1 and Asc1
4. dephosphorylate fragments and heat inactivate phosphatase(20 min, 80 C)
5. purify fragments(e.g. Qiaquick Gel Extraction Kit)
1. run 1 % agarose gel to estimate amount of fragment

20

Preparation of expression cassettes

1. take 100 µg of plasmid preparation from each of the following libraries
 - e) pMA-CAR
 - f) pCA-CAR
 - 25 g) Phaffia cDNA library
 - h) Carrot cDNA library
2. digest w. Srf1(10 units/prep, 37C overnight)
3. dephosphorylate (10 units/prep, 37C, 2h)
4. heat inactivate 80C, 20 min
- 30 5. concentrate and change buffer (precipitation or ultra filtration),
6. digest w. Asc1. (10 units/prep, 37 C, overnight)
7. adjust volume of preps to 100 µL

preparation of EVACs

35

Different types of EVACs have been made by varying the ratio of the different libraries that goes into the ligation reaction.

	pMA-CAR	pCA-CAR	Phaffia cDNA	Carrot cDNA
EVAC				
A	<u>40%</u>	<u>40%</u>	<u>10%</u>	<u>10%</u>
B	<u>25%</u>	<u>25%</u>	<u>25%</u>	<u>25%</u>

1. concentrate to < 32 μ L
2. add 1 unit of T4 DNA-ligase + 4 μ L 10x ligase buffer. Adjust to 40 μ L
3. ligate 2 h, 16 C
4. stop reaction by adding 2 μ L of 500 mM EDTA, heat inactivate 60C, 20 min
5. bring reaction volume to 500 μ L with dH₂O, concentrate to 30 μ L
6. add 10 U Asc1, 4 μ L 10X Asc1 buffer, bring to 40 μ L
7. incubate at 37C for 1h (alternatively 15 min 30 min)
8. heat inactivate 60C, 20 min
9. add 2 μ g YAC4-Asc arms, 1 U T4 DNA ligase, 10 μ L 10X ligase buffer, bring to 100 μ L
10. incubate ON, 16C
11. add water to 500 μ L
12. concentrate to 25 μ L
13. transform suitable yeast strain w. preparation using alkali/cation transformation or other suitable transformation method
14. plate on selective minimal media plates
15. incubate 30 C for 4-5 days
16. pick colonies
17. analyse colonies

Example 3

Preparation of EVACs (EVolvable Artificial Chromosomes) (Small scale preparation)

Preparation of expression cassettes

1. inoculate 5 ml of LB-medium (Sigma) with library inoculum corresponding to a 10+ fold representation of library. Grow overnight
2. make plasmid miniprep from 1.5 ml of culture (E.g. Qiaprep spin miniprep kit)

52

3. digest plasmid w. Srf 1
4. dephosphorylate fragments and heat inactivate phosphatase(20 min, 80 C)
5. digest w. Asc1
6. run 1/10 of reaction in 1% agarose to estimate amount of fragment

5

preparation of pYAC4-Asc arms

1. inoculate 150 ml of LB with a single colony of E. coli DH5 α containing pYAC4-Asc
2. grow to OD600 ~ 1, harvest cells and make plasmid preparation
- 10 3. digest 100 μ g pYAC4-Asc w. BamH1 and Asc1
4. dephosphorylate fragments and heat inactivate phosphatase(20 min, 80 C)
5. purify fragments(E.g. Qiaquick Gel Extraction Kit)
6. run 1 % agarose gel to estimate amount of fragment

15

preparation of EVACs

1. mix expression cassette fragments with YAC-arms so that cassette/arm ration is ~1000/1
2. if needed concentrate mixture(use e.g. Microcon YM30) so fragment concentration > 75 ng/ μ L reaction
- 20 3. add 1 U T4 DNA ligase, incubate 16C, 1-3 h . Stop reaction by adding 1 μ L of 500 mM EDTA
4. run pulsed field gel (CHEF III, 1% LMP agarose, 1/2 strength TBE, angle 120, temperature 12 C, voltage 5.6V/cm, switch time ramping 5 – 25 s, run time 30 h) Load sample in 2 lanes.
- 25 5. stain part of the gel that contains molecular weight markers
6. cut sample lanes corresponding to mw. 100 – 200 kb
7. agarase gel in high NaCl agarase buffer . 1 U agarase / 100 mg gel
8. concentrate preparation to < 20 μ L
9. transform suitable yeast strain w. preparation using electroporation
- 30 10. plate on selective minimal media plates
11. incubate 30 C for 4-5 days
12. pick colonies

35

Example 4: cDNA libraries used in the production of EVACs

1. *Daucus carota*, carrot root library:
 - Full length
 - Oligo dT primed, directional cDNA library
 - cDNA library made using a pool of 3 Evolva EVE 4, 5 & 8 vectors (Fig. 4, 5, 6)
 - Number of independent clones: 41.6×10^6
 - Average size: 0.9 – 2.9 kb
 - Number of different genes present: 5000 -10000

2. *Xanthophyllomyces dendrorhous*, (yeast), hole organism library
 - Full length
 - Oligo dT primed, directional cDNA library
 - cDNA library made using a pool of 3 Evolva EVE 4, 5 & 8 vectors (Fig. 4, 5, 6)
 - Number of independent clones: 48.0×10^6
 - Average size: 1.0 – 3.8 kb
 - Number of different genes present: 5000 -10000

3. Target carotenoid gene cDNA library
 - Full length and normalised
 - Directional cDNA cloning
 - Library made by cloning each gene individually in 2 Evolva EVE 4, 5 & 8 vectors (Fig. 4, 5, 6)
 - Number of different genes: 48
 - Species and genes used:
 - *Gentiana* sp., ggps, psy, pds, zds, lcy-b, lcy-e, bhy, zep
 - *Rhodobacter capsulatus*, idi, crtC, crtF
 - *Erwinia uredovora*, crtE, crtB, crtI, crtY, crtZ
 - *Nostoc anabaena*, zds
 - *Synechococcus* PGC7942, pds
 - *Erwinia herbicola*, crtE, crtB, crtI, crtY, crtZ
 - *Staphylococcus aureus*, crtM, crtN

54

- *Xanthophyllomyces dendrorhous*, crtI, crtYb
- *Capsicum annuum*, ccs, crtL
- *Nicotiana tabacum*, crtL, bchy
- *Prochlorococcus* sp., lcy-b, lcy-e
- 5 • *Saccharomyces cerevisiae*, idi
- *Corynebacterium* sp., crtI, crtYe, crtYf, crtEb
- *Lycopersicon esculentum*, psy-1
- *Neurospora crassa*, al1

10 **Example 5: Transformation of EVACs**

Example 5a: Transformation

1. Inoculate a single colony into 100 ml YPD broth and grow with aeration at 30°C to mid log, 2×10^6 to 2×10^7 cells/ml.
2. Spin to pellet cells at 400 x g for 5 minutes; discard supernatant.
- 15 3. Resuspend cells in a total of 9 ml TE, pH 7.5. Spin to pellet cells and discard supernatant.
4. Gently resuspend cells in 5 ml 0.1 M Lithium/Cesium Acetate solution, pH 7.5.
5. Incubate at 30°C for 1 hour with gentle shaking.
6. Spin at 400 x g for 5 minutes to pellet cells and discard supernatant.
- 20 7. Gently resuspend in 1 ml TE, pH 7.5. Cells are now ready for transformation.
8. In a 1.5 ml tube combine:
 - 100 µl yeast cells
 - 5 µl Carrier DNA (10 mg/ml)
 - 5 µl Histamine Solution
 - 25 • 1/5 of an EVAC preparation in a 10 µl volume (max). (One EVAC preparation is made of 100 µg of concatenation reaction mixture)
9. Gently mix and incubate at room temperature for 30 minutes.
10. In a separate tube, combine 0.8 ml 50% (w/v) PEG 4000 and 0.1 ml TE and 0.1 ml of 1 M LiAc for each transformation reaction. Add 1 ml of this PEG/TE/LiAc
- 30 mix to each transformation reaction. Mix cells into solution with gentle pipetting.
11. Incubate at 30°C for 1 hour.
12. Heat shock at 42°C for 15 minutes; cool to 30°C.
13. Pellet cells in a microcentrifuge at high speed for 5 seconds and remove supernatant.
- 35 14. Resuspend in 200 µl of rich media and plate in appropriate selective media

15. Incubate at 30°C for 48-72 hours until transformant colonies appear.

Example 5b: Transformation of EVACs using electroporation

5 100 ml of YPD is inoculated with one yeast colony and grown to $OD_{600} = 1.3$ to 1.5. The culture is harvested by centrifuging at $4000 \times g$ and 4°C. The cells are resuspended in 16 ml sterile H_2O . Add 2 ml $10 \times$ TE buffer, pH 7.5 and swirl to mix. Add 2 ml $10 \times$ lithium acetate solution (1 M, pH 7.5) and swirl to mix. Shake gently 45 min at 30°C. Add 1.0 ml 0.5 M DTE while swirling. Shake gently 15 min at 30°C.

10 The yeast suspension is diluted to 100 ml with sterile water. The cells are washed and concentrated by centrifuging at $4000 \times g$, resuspending the pellet in 50 ml ice-cold sterile water, centrifuging at $4000 \times g$, resuspending the pellet in 5 ml ice-cold sterile water, centrifuging at $4000 \times g$ and resuspending the pellet in 0.1 ml ice-cold sterile 1 M sorbitol. The electroporation was done using a *Bio-Rad Gene Pulser*. In a

15 sterile 1.5-ml microcentrifuge tube 40 μ l concentrated yeast cells were mixed with 5 μ l 1:10 diluted EVAC preparation. The yeast-DNA mix is transferred to an ice-cold 0.2-cm-gap disposable electroporation cuvette and pulsed at 1.5 kV, 25 μ F, 200 Ω . 1 ml ice-cold 1 M sorbitol is added to the cuvette to recover the yeast. Aliquots are spread on selective plates containing 1 M sorbitol. Incubate at 30°C until colonies

20 appear.

Example 6: Rare restriction enzymes with recognition sequence and cleavage points

In this example, rare restriction enzymes are listed together with their recognition sequence and cleavage points. (^) indicates cleavage points 5'-3' sequence and () indicates cleavage points in the complementary sequence.

25

W = A or T; N = A, C, G, or T

30 6a) Unique, palindromic overhang

35

AscI	GG^CGCG_CC
AsiSI	GCG_AT^CGC
CciNI	GC^GGCC_GC
CspBI	GC^GGCC_GC
FseI	GG_CCGG^CC
MchAI	GC^GGCC_GC
NotI	GC^GGCC_GC
PacI	TTA_AT^TAA

5	SbfI	CC_TGCA^GG
	SdaI	CC_TGCA^GG
	SgfI	GCG_AT^CGC
	SgrAI	CR^CCGG_YG
	Sse232I	CG^CCGG_CG
	Sse8387I	CC_TGCA^GG
10	6b)	No overhang
15	BstRZ246I	ATTT^AAAT
	BstSWI	ATTT^AAAT
	MspSWI	ATTT^AAAT
	MssI	GTTT^AAAC
	PmeI	GTTT^AAAC
20	SmiI	ATTT^AAAT
	SrfI	GCCC^GGGC
	SwaI	ATTT^AAAT
20	6c)	Non-palindromic and/or variable overhang
25	AarI	CACCTGCNNNN^NNNN_
	AbeI	CC^TCA_GC
	AloI	^NNNNN_NNNNNNGAACNNNNNNNTCCNNNNNNN_NNNNN^
	BaeI	^NNNNN_NNNNNNNNNACNNNNNGTAYCNNNNNNN_NNNNN^
	BbvCI	CC^TCA_GC
30	CpoI	CG^GWC_CG
	CspI	CG^GWC_CG
	Pfl27I	RG^GWC_CY
	PpiI	^NNNNN_NNNNNNGAACNNNNNCTCNNNNNNNN_NNNNN^
	PpuMI	RG^GWC_CY
35	PpuXI	RG^GWC_CY
	Psp5II	RG^GWC_CY
	PspPPI	RG^GWC_CY
	RsrII	CG^GWC_CG
	Rsr2I	CG^GWC_CG
40	SanDI	GG^GWC_CC
	SapI	GCTCTTCN^NNN_
	SdiI	GGCCN_NNN^NGGCC
	SexAI	A^CCWGG_T
	SfiI	GGCCN_NNN^NGGCC
45	Sse1825I	GG^GWC_CC
	Sse8647I	AG^GWC_CT
	VpaK32I	GCTCTTCN^NNN_
	6d)	Meganucleases
50	I-Sce I	TAGGGATAA_CAGG^GTAAT
	I-Ceu I	ACGGTC_CTAA^GGTAG
	I-Cre I	AAACGTC_GTGA^GACAGTTT
	I-Sce II	GGTC_ACCC^TGAAGTA
	I-Sce III	GTTTGG_TAAC^TATTTAT
55	Endo. Sce I	GATGCTGC_AGGC^ATAGGCTTGTTTA
	PI-Sce I	GG_GTGC^GGAGAA
	PI-Psp I	TGGCAAACAGCTA_TTAT^GGGTATTATGGGT
	I-Ppo I	CTCTC_TTAA^GGTAG
	HO	TTTCCGC_AACA^GT
60	I-Tev I	NN_NN^NNTCAGTAGATGTTTTCTTGGTCTACCGTTT

More meganucleases have been identified, but their precise sequence of recognition has not been determined, see e.g. www.meganuclease.com

5

Example 7: Concatemer size limitation experiments (use of stoppers)

Materials used:

10 pYAC4 (Sigma. Burke et al. 1987, science, vol 236, p 806) was digested w. EcoR1 and BamH1 and dephosphorylated

pSE420 (invitrogen) was linearised using EcoR1 and used as the model fragment for concatenation.

T4 DNA ligase (Amersham-pharmacia biotech) was used for ligation according to manufacturers instructions.

15

Method: Fragments and arms were mixed in the ratios(concentrations are arbitrary units) indicated on figures 9a and 9b. Ligation was allowed to proceed for 1 h at 16°C. Reaction was stopped by the addition of 1 µL 500 mM EDTA. Products were analysed by standard agarose GE (1 % agarose, ½ strength TBE) or by PFGE(CHEF III, 1% LMP agarose, ½ strength TBE, angle 120, temperature 12 C, voltage 5.6V/cm, switch time ramping 5 – 25 s, run time 30 h)

20

The results are shown in Figure 9, wherein it is shown that the size of concatemers is proportional to the ratio of cassettes per YAC arms.

25

Example 8: Integration of expression cassettes into artificial chromosomes

Integration of expression cassettes into YAC12 was done essentially as done by Sears D.D., Hieter P., Simchen G., Genetics, 1994, 138, 1055-1065.

30

An Ascl site was introduced into the Bgl II site of the integration vectors pGS534 and pGS525.

35

A β-galactosidase gene, as well as crtE, crtB, crtI and crtY from *Erwinia Uredovora* were cloned into pEVE4. These expression cassettes were ligated into Ascl of the modified integration vectors pGS534 and pGS525.

Linearised pGS534 and pGS525 containing the expression cassettes were transformed into haploid yeast strains containing the appropriate target YAC which carries the Ade^r gene. Red Ade⁻ transformants were selected (the parent host strain is red due to the ade2-101 mutation).

Additional confirmation of correct integration of the β -galactosidase expression cassette was done using a β -galactosidase assay.

Example 9: Re-transformation of cells that already contain Artificial chromosomes to obtain at least 2 artificial chromosomes per cell

Yeast strains containing YAC12, Sears D.D., Hieter P., Simchen G., Genetics, 1994, 138, 1055-1065 were transformed with EVACs following the protocol described in example 4a. The transformed cells were plated on plates that select for cells that contained both YAC12 and EVACs.

Example 10: Example of different expression patterns "phenotypes" obtained using the same yeast clones under different expression conditions:

Colonies were picked with a sterile toothpick and streaked sequentially onto plates corresponding to the four repressed and/or induced conditions (-Ura/-Trp, -Ura/-Trp/-Met, -Ura/-Trp/+200 μ M Cu₂SO₄, -Ura/-Trp/-Met/+200 μ M Cu₂SO₄). 20 mg adenin was added to the media to suppress the ochre phenotype.

Claims

1. A nucleotide concatemer comprising in the 5'→3' direction a cassette of nucleotide sequence of the general formula

5

$$[rs_2\text{-}SP\text{-}PR\text{-}X\text{-}TR\text{-}SP\text{-}rs_1]_n$$

wherein

10

rs_1 and rs_2 together denote a functional restriction site,
SP individually denotes a spacer of at least two nucleotide bases,
PR denotes a promoter, capable of functioning in a cell,
X denotes an expressible nucleotide sequence,
TR denotes a terminator, and

15

SP individually denotes a spacer of at least two nucleotide bases, and
 $n \geq 2$, and
wherein at least a first cassette is different from a second cassette.

20

2. The concatemer according to claim 1, wherein the nucleotide sequence comprises a DNA sequence selected from the group comprising cDNA, genomic DNA.

25

3. The concatemer according to claim 1, wherein the nucleotide sequence is single stranded, or partly single stranded.

30

4. The concatemer according to claim 1, wherein the nucleotide sequence is double stranded.
5. The concatemer according to any of the preceding claims 1 to 4, comprising nucleotide sequences from at least one expression state.
6. The concatemer according to any of the preceding claims 1 to 5, comprising nucleotide sequences from at least two expression states.

60

7. The concatemer according to any of the preceding claims 1 to 6, wherein the rs_1 - rs_2 restriction site of at least two cassettes are recognised by the same restriction enzyme, more preferably are identical.
- 5 8. The concatemer according to claim 7, wherein the rs_1 - rs_2 restriction site of essentially all cassettes are recognised by the same restriction enzyme, more preferably are identical.
9. The concatemer according to any of the preceding claims 1 to 8, wherein
10 substantially all cassettes are different.
10. The concatemer according to any of claims 1 to 9, wherein at least one cassette comprises an intron between the promoter and the expressible nucleotide sequence, more preferably substantially all cassettes comprise an intron
15 between the promoter and the expressible nucleotide sequence.
11. The concatemer according to any of the preceding claims 1 to 10, wherein the difference comprises different promoters, and/or different expressible nucleotide sequences, and/or different spacers and/or different terminators and/or different
20 introns.
12. The concatemer according to any of the preceding claims 1 to 11, wherein n is at least 10, such as at least 15, for example at least 20, such as at least 25, for example at least 30, such as from 30 to 60 or more than 60, such as at least 75,
25 for example at least 100, such as at least 200, for example at least 500, such as at least 750, for example at least 1000, such as at least 1500, for example at least 2000.
13. The concatemer according to any of the preceding claims 1 to 12, wherein at
30 least one cassette comprise the cassette from a primary vector according to claims 63 to 98, more preferably substantially all cassettes comprise the cassette from a primary vector according to claims 63 to 98.
14. The concatemer according to any of the preceding claims 1 to 13, comprised in
35 an artificial chromosome.

15. The concatemer according to claim 14, wherein the artificial chromosome is selected from the group comprising a Yeast Artificial Chromosome, a mega Yeast Artificial Chromosome, a Bacterial Artificial Chromosome, a mouse artificial chromosome, a Mammalian Artificial Chromosome, an Insect Artificial Chromosome, an Avian Artificial Chromosome, a Bacteriophage Artificial Chromosome, a Baculovirus Artificial Chromosome, or a Human Artificial Chromosome.
16. The concatemer according to any of the preceding claims 1 to 13, comprised in a plasmid or an insertion vector, such as for example yeast integrative plasmid (YIp), Yeast replicating plasmid (YRp), Yeast Episomal plasmid (YEp), Yeast centromeric plasmid (YCp), Yeast linear plasmid (YLp), Yeast expression plasmid (YXp), Yeast retrotransposons (Ty elements), Yeast killer plasmid, Yeast disintegration plasmid (YDp).
17. The concatemer according to any of claims 13 to 16, wherein the vector further comprises at least one selectable genetic marker, such as a repressive or a dominant marker.
18. The concatemer according to claim 17, comprising two selectable genetic markers.
19. The concatemer according to claim 17 or 18, wherein the marker comprises a marker selected from the group comprising LEU 2, TRP 1, HIS 3, LYS 2, URA 3, ADE 2, Amyloglucosidase, β -lactamase, CUP 1, G418^R, TUN^R, KILk1, C230, SMR1, SFA, Hygromycin^R, methotrexate^R, chloramphenicol^R, Diuron^R, Zeocin^R, Canavanine^R.
20. The concatemer according to any of claims 1 to 19, wherein different expressible nucleotide sequences come from the same or from different expression states.
21. The concatemer according to claim 20, wherein the different expression states represent at least two different tissues, such as at least two organs, such as at least two species, such as at least two genera.

22. The concatemer according to claim 21, wherein the different species are from at least two different phylae, such as from at least two different classes, such as from at least two different divisions, more preferably from at least two different sub-kingdoms, such as from at least two different kingdoms.
23. The concatemer according to claim 21, wherein one species is a eukaryot and another species is a prokaryot.
24. The concatemer according to any of the preceding claims 1 to 23, being designed to minimise the level of repeat sequences occurring in the concatemer.
25. A method for concatenation comprising the steps of concatenating at least two cassettes of nucleotide sequences each cassette comprising a first sticky end, a spacer sequence, a promoter, an expressible nucleotide sequence, a terminator, a spacer sequence, and a second sticky end.
26. The method according to claim 25, further comprising
starting from a primary vector [RS1-RS2-SP-PR-X-TR-SP-RS2'-RS1'],
wherein X denotes an expressible nucleotide sequence,
RS1 and RS1' denote restriction sites,
RS2 and RS2' denote restriction sites different from RS1 and RS1',
SP individually denotes a spacer sequence of at least two nucleotides,
PR denotes a promoter,
TR denotes a terminator,
iii) cutting the primary vector with the aid of at least one restriction enzyme specific for RS2 and RS2' obtaining cassettes having the general formula [rs₂-SP-PR-X-TR-SP-rs₁] wherein rs₁ and rs₂ together denote a functional restriction site RS2 or RS2',
iv) assembling the cut out cassettes through interaction between rs₁ and rs₂.
27. The method according to claim 25 or 26, comprising concatenating at least at least 10 cassettes, such as at least 15, for example at least 20, such as at least 25, for example at least 30, such as from 30 to 60 or more than 60, such as at

least 75, for example at least 100, such as at least 200, for example at least 500, such as at least 750, for example at least 1000, such as at least 1500, for example at least 2000.

- 5 28. The method according to claim 26, further comprising addition of vector arms each having a RS2 or RS2' in one end and a non-complementary overhang or a blunt end in the other end.
- 10 29. The method according to claim 27, whereby the ratio of vector arms to cassettes determines the number of cassettes in the concatemer.
30. The method according to claim 27 or 29, wherein the vector arms are artificial chromosome vector arms.
- 15 31. The method according to claim 26, further comprising addition of stopper fragments, the stopper fragments each having a RS2 or RS2' in one end and a non-complementary overhang or a blunt end in the other end.
- 20 32. The method according to claim 31, further comprising ligating vector arms to the stopper fragments.
- 25 33. The method according to claim 26, further comprising
- iv) isolating mRNA from an expression state,
 - v) obtaining substantially full length cDNA clones corresponding to the mRNA sequences,
 - vi) inserting the substantially full length cDNA clones into a cloning site in a cassette in a primary vector, said cassette being of the general formula in 5'→3' direction:
[RS1-RS2-SP-PR-CS-TR-SP-RS2'-RS1']
- 30 wherein CS denotes a cloning site.
34. The method according to claim 26, wherein RS1 and RS1' are restriction sites leaving blunt ends, and RS2 and RS2' are restriction sites leaving compatible sticky ends.

35. The method according to claim 26, wherein RS1 and RS1' are identical, and wherein RS2 and RS2' are identical.
36. The method according to claim 26, wherein RS2 and RS2' have palindromic overhangs.
37. The method according to claim 26, wherein RS2 and RS2' have non-palindromic overhangs.
38. The method according to any of the preceding claims 25 to 37, further comprising selection of vectors having expressible nucleotide sequences from at least two different expression states, such as from two different species.
39. The method according to claim 38, whereby the two different species are from two different classes, such as from two different divisions, more preferably from two different sub-kingdoms, such as from two different kingdoms.
40. The method according to any of the claims 25 to 39, whereby the concatemer is ligated into an artificial chromosome selected from the group comprising yeast artificial chromosome, mega yeast artificial chromosome, bacterial artificial chromosome, mouse artificial chromosome, human artificial chromosome.
41. The method according to any of the preceding claims 26 to 40, whereby RS2 and RS2' in at least two cassettes are cleaved by one restriction enzyme, preferably RS2 and RS2' in substantially all cassettes are cleaved by one restriction enzyme.
42. A cell comprising at least one concatemer of individual oligonucleotide cassettes, each concatemer comprising oligonucleotide of the following formula in 5'→3' direction:
- $$[rs_2\text{-}SP\text{-}PR\text{-}X\text{-}TR\text{-}SP\text{-}rs_1]_n$$
- wherein
- rs₁ and rs₂ together denote a restriction site,
- SP individually denotes a spacer of at least two nucleotide bases,

65

PR denotes a promoter, capable of functioning in the cell,

X denotes an expressible nucleotide sequence,

TR denotes a terminator, and

SP individually denotes a spacer of at least two nucleotide bases,

5 wherein $n \geq 2$, and

wherein at least two expressible nucleotide sequences are from different expression states.

10 43. A cell comprising at least one concatemer of individual oligonucleotide cassettes, each concatemer comprising oligonucleotide of the following formula in 5'→3' direction:

$[rs_2\text{-}SP\text{-}PR\text{-}X\text{-}TR\text{-}SP\text{-}rs_1]_n$

wherein

rs_1 and rs_2 together denote a restriction site,

15 SP individually denotes a spacer of at least two nucleotide bases,

PR denotes a promoter, capable of functioning in the cell,

X denotes an expressible nucleotide sequence,

TR denotes a terminator, and

20 SP individually denotes a spacer of at least two nucleotide bases,

wherein $n \geq 2$, and

wherein $rs_1\text{-}rs_2$ in at least two cassettes is recognised by the same restriction enzyme.

25 44. The cell according to claim 422 or 433, wherein substantially all $rs_1\text{-}rs_2$ sequences are recognised by the same restriction enzyme, more preferably wherein substantially all $rs_1\text{-}rs_2$ sequences are substantially identical.

30 45. The cell according to any of claims 422 to 444, wherein n is at least 10, such as at least 15, for example at least 20, such as at least 25, for example at least 30, such as from 30 to 60 or more than 60, such as at least 75, for example at least 100, such as at least 200, for example at least 500, such as at least 750, for example at least 1000, such as at least 1500, for example at least 2000.

35 46. The cell according to any of claims 422 to 455, comprising 2 concatemers per cell, for example 3 per cell, such as at least 4 per cell.

47. The cell according to any of claims 422 to 466, wherein at least one cassette comprises an intron between the promoter and the expressible nucleotide sequence, more preferably substantially all cassettes comprise an intron between the promoter and the expressible nucleotide sequence.
48. The cell according to any of claims 433 to 477, comprising a eukaryotic cell selected from the group comprising: yeasts; filamentous ascomycetes such as *Neurospora crassa* and *Aspergillus nidulans*; plant cells such as those derived from *Nicotiana* and *Arabidopsis*; mammalian host cells such as those derived from humans, monkeys and rodents, such as chinese hamster ovary (CHO) cells, NIH/3T3, COS, 293, VERO, HeLa.
49. The cell according to claim 488, being a yeast cell selected from the group comprising baker's yeast, *Kluyveromyces marxianus*, *K. lactis*, *Candida utilis*, *Phaffia rhodozyma*, *Saccharomyces boulardii*, *Pichia pastoris*, *Hansenula polymorpha*, *Yarrowia lipolytica*, *Candida paraffinica*, *Schwanniomyces castellii*, *Pichia stipitis*, *Candida shehatae*, *Rhodotorula glutinis*, *Lipomyces lipofer*, *Cryptococcus curvatus*, *Candida* spp. (e.g. *C. palmioleophila*), *Yarrowia lipolytica*, *Candida guilliermondii*, *Candida*, *Rhodotorula* spp., *Saccharomycopsis* spp., *Aureobasidium pullulans*, *Candida brumptii*, *Candida hydrocarbofumarica*, *Torulopsis*, *Candida tropicalis*, *Saccharomyces cerevisiae*, *Rhodotorula rubra*, *Candida flaveri*, *Eremothecium ashbyii*, *Pichia* spp., *Kluyveromyces*, *Hansenula*, *Kloeckera*, *Pichia*, *Pachysolen* spp., or *Torulopsis bombicola*.
50. The cell according to any of the preceding claims 433 to 49, having a mutation in a central biosynthetic pathway.
51. The cell according to claim 500, comprising an inserted selectable genetic marker complementing the mutation.
52. The cell according to any of the preceding claims 433 to 511, comprising a selectable genetic marker.

67

53. The cell according to any of claims 433 to 522, wherein the nucleotide sequence of at least one concatemer, preferably the nucleotide sequence from substantially all concatemers have been designed to minimise the level of repeat sequences in any one concatemer.

5

54. The cell according to claim 533, wherein recombination within the expressible nucleotide sequence has been minimised.

55. The cell according to any of the preceding claims 433 to 544, wherein at least one concatemer, preferably substantially all concatemers is/are concatemer/s according to claims 1 to 24.

10

56. A method for producing a transgenic cell comprising inserting into a host cell a concatemer comprising a heterologous nucleotide sequence comprising at least two genes each controlled by a promoter, wherein the two promoters are different.

15

57. The method according to claim 566, whereby the inserted genes come from at least two different expression states.

20

58. The method according to claim 57, whereby the expression states are comprised in different species.

59. The method according to claim 588, whereby the different species are comprised in different kingdoms.

25

60. The method according to any of the preceding claims 566 to 59, comprising insertion of a concatemer according to claims 1 to 24.

61. The method according to any of the preceding claims 566 to 600, further comprising selecting for cells comprising at least one stably maintained concatemer,

30

35

68

62. The method according to claim 611, whereby selection comprises selection of cells carrying at least one selectable genetic marker on an artificial chromosome, more preferably two selectable genetic markers on an artificial chromosome.

5

63. A primary vector comprising a nucleotide sequence cassette of the general formula in 5'→3' direction:

[RS1-RS2-SP-PR-CS-TR-SP-RS2'-RS1']

wherein

10

RS1 and RS1' denote restriction sites,

RS2 and RS2' denotes restriction sites different from RS1 and RS1',

SP individually denotes a spacer sequence of at least two nucleotides,

PR denotes a promoter,

15

CS denotes a cloning site,

TR denotes a terminator.

64. The vector according to claim 633, wherein the nucleotide sequence is a DNA sequence.

20

65. The vector according to claim 633, wherein the nucleotide sequence is double stranded.

66. The vector according to any of the preceding claims 633 to 655, further comprising an intron sequence between the promoter and the cloning site and/or between the cloning site and the terminator.

25

67. The vector according to any of the preceding claims 633 to 666, wherein the cloning site comprises an expressible nucleotide sequence.

30

68. The vector according to claim 677, wherein in the expressible nucleotide sequence comprises substantially full length cDNA.

69. The vector according to claim 677, wherein the expressible nucleotide sequence comprises genomic DNA.

35

69

70. The vector according to any of the preceding claims 633 to 69, wherein any of RS1, RS1', RS2, RS2' comprise a rare restriction site selected from those of Example 6.
- 5 71. The vector according to claim 700, wherein the recognition sequence for RS1, RS1', RS2 and/or RS2' comprise at least 6 bases such as at least 8 bases, for example at least 10 bases.
- 10 72. The vector according to claim 711, wherein the recognition sequence comprises a bipartite sequence.
73. The vector according to claim 711, wherein the GC content of the recognition sequence is more than 40%, preferably more than 50%, more preferably equal to or more than 60%.
- 15 74. The vector according to any of the preceding claims 633 to 733, wherein the restriction enzyme recognising RS2 and RS2' produces sticky ends upon cleavage of a double stranded nucleotide sequence, preferably wherein the sticky ends have a pre-determined nucleotide sequence.
- 20 75. The vector according to any of the preceding claims 633 to 744, wherein RS2 and RS2' are identical.
76. The method according to claim 755, wherein the RS2 and/or RS2' overhang is a
- 25 palindromic sequence.
77. The method according to claim 755, wherein the RS2 and/or RS2' overhang is a non-palindromic sequence.
- 30 78. The vector according to any of the preceding claims 633 to 755, wherein the restriction enzyme recognising RS1 and RS1' produces blunt ends upon cleavage of a double stranded nucleotide sequence
- 35

70

79. The vector according to any of the preceding claims 633 to 755, wherein the restriction enzyme recognising RS1 and 'RS1' produces sticky ends with a nucleotide sequence being non-compatible with the nucleotide sequence of sticky ends produced upon cleavage of RS2 and RS2'.
- 5
80. The vector according to any of the preceding claims 633 to 79, wherein RS1 and RS1' are identical.
81. The vector according to any of the preceding claims 633 to 800, further comprising a spacer sequence between TR and RS2'.
- 10
82. The vector according to any of the preceding claims 633 to 811, wherein the spacer and the optional spacer sequence together comprise at least 100 bases, such as at least 250 bases, such as at least 500 bases, such as at least 750 bases, for example at least 1000 bases, such as at least 1100 bases, for example at least 1200 bases, such as at least 1300 bases, for example at least 1400 bases, such as at least 1500 bases, for example at least 1600 bases, such as at least 1700 bases, for example at least 1800 bases, such as at least 1900 bases, for example at least 2000 bases, such as at least 2100 bases, for example at least 2200 bases, such as at least 2300 bases, for example at least 2400 bases, such as at least 2500 bases, for example at least 2600 bases, such as at least 2700 bases, for example at least 2800 bases, such as at least 2900 bases, for example at least 3000 bases, such as at least 3200 bases, for example at least 3500 bases, such as at least 3800 bases, for example at least 4000 bases, such as at least 4500 bases, for example at least 5000 bases, such as at least 6000 bases.
- 15
- 20
- 25
83. The vector according to claims 811 or 822, wherein at least one of the spacer sequences comprises between 100 and 2500 bases, preferably between 200 and 2300 bases, more preferably between 300 and 2100 bases, such as between 400 and 1900 bases, more preferably between 500 and 1700 bases, such as between 600 and 1500 bases, more preferably between 700 and 1400 bases.
- 30

35

84. The vector according to any of the preceding claims 633 to 833, wherein the promoter is an externally controllable promoter.
85. The vector according to any of the preceding claims 633 to 844, wherein the promoter comprises an inducible promoter or wherein the promoter comprises a repressible promoter.
86. The vector according to any of the preceding claims 633 to 855, wherein the promoter comprises both repressible and inducible elements.
87. The vector according to any of the preceding claims 633 to 866, wherein the promoter is chemically inducible and/or repressible and/or inducible/repressible by temperature.
88. The vector according to any of the preceding claims 633 to 877, wherein the promoter is induced and/or repressed by any factor selected from the group comprising carbohydrates, e.g. galactose; low inorganic phosphase levels; temperature, e.g. low or high temperature shift; metals or metal ions, e.g. copper ions; hormones, e.g. dihydrotestosterone; deoxycorticosterone; heat shock (e.g. 39°C); methanol; redox-status; growth stage, e.g. developmental stage; synthetic inducers, e.g. the gal inducer.
89. The vector according to any of the preceding claims 633 to 888, wherein the promoter comprises a promoter selected from the group comprising ADH 1, PGK 1, GAP 491, TPI, PYK, ENO, PMA 1, PHO5, GAL 1, GAL 2, GAL 10, MET25, ADH2, MEL 1, CUP 1, HSE, AOX, MOX, SV40, CaMV, Opaque-2, GRE, ARE, PGK/ARE hybrid, CYC/GRE hybrid, TPI/ α 2 operator, AOX 1, MOX A.
90. The vector according to claim 889, wherein the promoter is selected from hybrid promoters including PGK/ARE hybrid, CYC/GRE hybrid.
91. The vector according to any of the preceding claims 633 to 900, wherein the promoter is a synthetic promoter.

92. The vector according to any of the preceding claims 633 to 911, wherein the cloning site allows directional cloning.
- 5 93. The vector according to any of the preceding claims 633 to 922, wherein the cloning site comprises multiple cloning sites, such as a polylinker site, the cloning site preferably encoding a series of restriction endonuclease recognition sites.
- 10 94. The vector according to any of the preceding claims 633 to 933, wherein the promoter and terminator are capable of functioning in an expression host cell, preferably in a yeast cell.
- 15 95. The vector according to any of the preceding claims 633 to 944, wherein the primary vector comprising the cassette is a plasmid vector having a high copy number, being capable of being propagated in *E. coli*, and having a selectable marker for maintenance in *E. coli*.
- 20 96. The vector according to claim 955, wherein the primary vector can be made single-stranded.
- 25 97. The vector according to claim 966, further comprising an origin of replication in the vector backbone, preferably an origin of replication for filamentous phages, more preferably the f1 origin of replication.
- 30 98. The vector according to claim 955, wherein the primary vector is selected from the group comprising pBR322, pUC18, pUC19, pUC118, pUC119, pEMBL, pRSA101, pBluescript.
99. The vector according to claim 633, as defined by any of the sequences SEQ ID NO 1 to 3.
100. A method of preparing a primary vector comprising inserting an expressible nucleotide sequence into a cloning site in a primary vector comprising a cassette, the cassette comprising a nucleotide sequence of the general formula in 5'→3' direction:
[RS1-RS2-SP-PR-CS-TR-SP-RS2'-RS1']
- 35

wherein

RS1 and RS1' denote restriction sites,

RS2 and RS2' denotes restriction sites different from RS1 and RS1',

5 SP individually denotes a spacer sequence of at least two nucleotides,

PR denotes a promoter,

CS denotes a cloning site,

TR denotes a terminator.

10 101. The method according to claim 1000, wherein the expressible nucleotide sequences comprise genomic DNA.

102. The method according to claim 1000, further comprising
isolating total mRNA from an expression state, and
15 obtaining full length cDNA for insertion into the vector.

103. The method according to claim 1022, further comprising selection of cDNA to obtain substantially full length cDNA.

20 104. The method according to any of the preceding claims 1000 to 1033, whereby the insertion into the primary vector comprises directional cloning.

105. The method according to any of the preceding claims 1000 to 1044, whereby a substantially full length cDNA population comprises a normalised
25 representation of cDNA species.

106. The method according to any of the preceding claims 1000 to 1055, whereby a substantially full length cDNA population comprises an ormalised
representation of cDNA species characteristic of a given expression state.

30 107. A nucleotide library comprising at least two primary vectors each vector comprising a nucleotide sequence cassette of the general formula in 5'→3' direction:

[RS1-RS2-SP-PR-X-TR-SP-RS2'-RS1']

35 wherein

RS1 and RS1' denote restriction sites,
RS2 and RS2' denote restriction sites different from RS1 and RS1',
SP individually denotes a spacer sequence of at least two nucleotides,
5 PR denotes a promoter,
X denotes an expressible nucleotide sequence,
TR denotes a terminator.

– wherein the expressible nucleotide sequences are isolated from at least one expression state,

10 – and wherein at least a first and a second primary vector comprise an expressible nucleotide sequence coding for the same peptide under the control of two different promoters in said first and second primary vector.

108. The library according to claim 1077, wherein at least three primary
15 vectors comprise an expressible nucleotide sequence coding for the same peptide under the control of three different promoters.

109. The library according to claim 1077, wherein at least four primary
20 vectors comprise an expressible nucleotide sequence coding for the same peptide under the control of four different promoters.

110. The library according to claim 1077, wherein at least five primary
vectors comprise an expressible nucleotide sequence coding for the same
peptide under the control of five different promoters, such as wherein at least six
25 primary vectors comprise an expressible nucleotide sequence coding for the
same peptide under the control of six different promoters, for example wherein
at least seven primary vectors comprise an expressible nucleotide sequence
coding for the same peptide under the control of seven different promoters, for
example wherein at least eight primary vectors comprise an expressible
30 nucleotide sequence coding for the same peptide under the control of eight
different promoters, such as wherein at least nine primary vectors comprise an
expressible nucleotide sequence coding for the same peptide under the control
of nine different promoters, for example wherein at least ten primary vectors
comprise an expressible nucleotide sequence coding for the same peptide under
35 the control of ten different promoters.

111. The library according to any of the preceding claims 1077 to 1100, wherein the expressible nucleotide sequence coding for the same peptide comprises essentially the same nucleotide sequence, more preferably the same nucleotide sequence.
112. The library according to any of the preceding claims 1077 to 1111, being maintained in a host cell capable of maintaining the vectors comprising the cassettes substantially unaltered.
113. The library according to claim 1122, wherein the host cell is selected from the group comprising bacteria such as *E. coli* or *Bacillus subtilis*, or fungi such as yeast.
114. The library according to any of claims 1077 to 1133, wherein the promoters are not functional in the library host.
115. The library according to any of the preceding claims 1077 to 1144, wherein RS2 and RS2' are identical.
116. The library according to claim 1155, wherein at least two vectors comprise the same RS2 and RS2' sequence.
117. The library according to claim 1166, wherein substantially all vectors comprise the same RS2 and RS2' sequence.
118. The library according to any of the preceding claims 1077 to 1177, comprising at least one primary vector according to claims 633 to 988.
119. A method for preparing a nucleotide library comprising obtaining expressible nucleotide sequences, cloning the expressible nucleotide sequences into cloning sites of a mixture of primary vectors, the primary vectors comprising a cassette, the cassettes comprising a nucleotide sequence of the general formula in 5'→3' direction:
- [RS1-RS2-SP-PR-CS-TR-SP-RS2'-RS1']

wherein

RS1 and RS1' denote restriction sites,

RS2 and RS2' denote restriction sites different from RS1 and RS1',

5 SP individually denotes a spacer sequence of at least two nucleotides,

PR denotes a promoter,

CS denotes a cloning site,

TR denotes a terminator,

10 and transferring the primary vectors into a host cell.

120. The method according to claim 11919, whereby the expressible nucleotide sequences comprises cDNA, and/or genomic DNA.

15 121. The method according to claim 11919, whereby the expressible nucleotide sequences are obtained from a cDNA library.

122. The method according to any of the claims 11919 to 1211, wherein the expressible nucleotide sequences are representative of an expression state.

Fig. 1

Constructing entry libraries




Fig. 2a




Fig. 2b




Fig. 3

Model Entry Vector





Fig. 4


EVE4 entry vector



6/13

Fig. 5

EVE5 entry vector



7/13

Fig. 6

EVE8 entry vector





Fig. 7


pYAC4-AscI
Vector for providing EVACS arms



9/13


Fig. 8

Synthesis of Concatemers




10/13

Fig. 9a



11/13

Fig. 9b



12/13

Fig. 10





Fig. 11



SEQUENCE LISTING

<110> Evolva Biotech AS
Goldsmith, Neil
Sørensen, Alexandra M. P.
Nielsen, Søren V.S.
Naesby, Michael

<120> Concatemers of differentially expressed multiple genes

<130> P 500 PC00

<150> DK PA 2001 00127
<151> 2001-01-25

<150> US 60/301,022
<151> 2001-06-27

<160> 4

<170> PatentIn version 3.1

<210> 1
<211> 3417
<212> DNA
<213> Synthetic

<220>
<221> misc_feature
<222> (1902)..(2759)
<223> Ampicillin resistance gene

<220>
<221> rep_origin
<222> (959)..(1899)
<223> ColE1

<220>
<221> misc_feature
<222> (2891)..(3347)
<223> f1-phage origin of replication

<220>
<221> terminator
<222> (495)..(823)
<223> ADH1

<220>

<221> promoter
<222> (49)..(437)
<223> Met25 promoter

<400> 1
ctgatttgcc cgggcagttc aggctcatca ggcgcgccat gcagggattc ttcggatg
ca
60
agggttcgaa tcccttagct ctcattatct tttgcttttt ctcttgaggt cacatgat
cg
120
caaaatggca aatggcacgt gaagctgtcg atattgggga actgtggtgg ttggcaaa
tg
180
actaattaag ttagtcaagg cgccatcctc atgaaaactg tgtaacataa taaccgaa
gt
240
gtcgaaaagg tggcaccttg tccaattgaa cacgctcgat gaaaaaaata agatatat
at
300
aagggttaagt aaagcgtctg ttagaaagga agtttttctt ttttcttgct ctcttgct
tt
360
ttcatctact atttccttcg tgtaatacag ggtcgtcaga tacatagata caattcta
tt
420
acccccatcc atacaagctt ggcgcgcaat tcgtcgaccc ggggatccgc ggccgcag
gc
480
ctaaattgat ctagagcttt ggacttcttc gccagagggt tggtaagtc tccaatca
ag
540
gttgctcggct tgtctacctt gccagaaatt tacgaaaaga tggaaaaggg tcaaactg
tt
600
ggtagatacg ttgttgacac ttctaaataa gcgaatttct tatgatttat gattttta
tt
660
attaaataag ttataaaaaa aataagtgtg taaaaatttt aaagtgactc ttaggttt
ta

720

aaacgaaaat tcttggttctt gagtaactct ttctgtagg tcagggttgc ttctcagg
ta

780

tagcatgagg tcgctcttat tgaccacacc tctaccggca tgcccatggg ttaactga
tc

840

aatgcacact gcatggcgcg cctgatgagc ctgaactgcc cgggcaaata agctggac
gt

900

ctgcctgcat taatgaatcg gccaacgcgc ggggagaggc ggtttgcgta ttgggcgc
tc

960

ttccgcttcc tcgctcactg actcgctgcg ctgggtcggt cggctgcggc gagcggta
tc

1020

agctcactca aaggcggtaa tacgggttat cacagaatca ggggataacg caggaaag
aa

1080

catgtgagca aaaggccagc aaaaggccag gaaccgtaaa aaggccgcgt tgctggcg
tt

1140

tttccatagg ctccgcccc ctgacgagca tcacaaaaat cgacgctcaa gtcagagg
tg

1200

gcgaaacccg acaggactat aaagatacca ggcgtttccc cctggaagct cctcgtg
cg

1260

ctctcctggt ccgacctgc cgcttaccgg atacctgtcc gcotttctcc cttcggga
ag

1320

cgtggcgctt tctcatagct cacgctgtag gtatctcagt tcggtgtagg tcgttcgc
tc

1380

caagctgggc tgtgtgcacg aacccccgt tcagcccgac cgtgcgcct tatccggt
aa

1440

ctatcgtctt gagtccaacc cggttaagaca cgacttatcg ccaactggcag cagccact
gg

1500

taacaggatt agcagagcga ggtatgtagg cgggtgctaca gagttcttga agtggtgg
cc

1560

taactacggc tacactagaa ggacagtatt tggtatctgc gctctgctga agccagtt
ac

1620

cttcggaaaa agagttggta gctcttgatc cggcaaacaa accaccgctg gtagcggg
gg

1680

tttttttggg tgcaagcagc agattacgcg cagaaaaaaaa ggatctcaag aagatcct
tt

1740

gatcttttct acgggggtctg acgctcagtg gaacgaaaac tcacgttaag ggattttg
gt

1800

catgagatta tcaaaaagga tcttcaccta gatcctttta aattaaaaat gaagtttt
aa

1860

atcaatctaa agtatatatg agtaaacttg gtctgacagt taccaatgct taatcagt
ga

1920

ggcacctatc tcagcgatct gtctatttcg ttcattccata gttgcctgac tccccgtc
gt

1980

gtagataact acgatacggg agggcttacc atctggcccc agtgctgcaa tgataccg
cg

2040

agaccacgc tcaccggctc cagatttatc agcaataaac cagccagccg gaagggcc
ga

2100

gcgcagaagt ggtcctgcaa ctttatccgc ctccatccag tctattaatt gttgcggg
ga

2160

agctagagta agtagttcgc cagttaatag tttgcgcaac gttggtgcca ttgctaca
gg

2220

catcgtgggtg tcacgctcgt cgtttggtat ggcttcattc agctccgggt cccaacga
tc

2280

aaggcgagtt acatgatccc ccatgttggtg caaaaaagcg gttagctcct tcggctcct
cc
2340

gatcggtgtc agaagtaagt tggccgcagt gttatcactc atgggttatgg cagcactg
ca
2400

taattctcctt actgtcatgc catccgtaag atgcttttct gtgactgggtg agtactca
ac
2460

caagtcattc tgagaatagt gtatgcggcg accgagttgc tcttgcccgg cgtcaata
cg
2520

ggataatacc gcgccacata gcagaacttt aaaagtgtc atcattggaa aacgttct
tc
2580

ggggcgaaaa ctctcaagga tcttaccgct gttgagatcc agttcgatgt aaccact
cg
2640

tgcacccaac tgatcttcag catcttttac tttcaccagc gtttctgggt gagcaaaa
ac
2700

aggaaggcaa aatgccgcaa aaaagggaat aaggcgaca cggaaatgtt gaatactc
at
2760

actcttcctt tttcaatatt attgaagcat ttatcagggt tattgtctca tgagcgga
ta
2820

catatttgaa tgtatttaga aaaataaaca aataggggtt ccgcgcacat ttccccga
aa
2880

agtgccacct gacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg tggttacg
cg
2940

cagcgtgacc gctacacttg ccagcgccct agcgcgcgct cctttcgctt tcttcctt
tc
3000

ctttctcgcc acgttcgcgc gctttccccg tcaagctcta aatcgggggc tcccttta
gg

3060

gttcgattt agtgctttac ggcacctga ccccaaaaaa cttgattagg gtgatggg
tc
3120

acgtagtggg ccatcgccct gatagacggg ttttcgccct ttgacgttgg agtccacg
tt
3180

ctttaatagt ggactcttgt tccaaactgg aacaacactc aaccctatct cggctctat
tc
3240

ttttgattta taagggattt tgccgatttc ggctatttgg ttaaaaaatg agctgatt
ta
3300

acaaaaattt aacgcgaatt ttaacaaaat attaacgctt acaatttcca ttcgccat
tc
3360

aggctgcgca actgttggga agggcgatcg gtgcgggcct cttegetatt acgccag
3417

<210> 2
<211> 3501
<212> DNA
<213> Synthetic

<220>
<221> misc_feature
<222> (1986)..(2843)
<223> Ampicillin resistance gene

<220>
<221> rep_origin
<222> (1043)..(1983)
<223> ColE1

<220>
<221> misc_feature
<222> (2975)..(3431)
<223> f1-phage origin of replication

<220>
<221> terminator

<222> (579)..(907)

<223> ADH1

<220>

<221> promoter

<222> (49)..(519)

<223> Cup1 promoter

<400> 2

ctgatttgcc cgggcagttc aggctcatca ggcgcgccat gcagggataa gccgatcc
ca
60

ttaccgacat ttgggcgcta tacgtgcata tgttcatgta tgtatctgta tttaaaac
ac
120

ttttgtatta tttttcctca tatatgtgta taggtttata cggatgattt aattatta
ct
180

tcaccaccct ttatttcagg ctgatatctt agccttggtta ctagttagaa aaagacat
tt
240

ttgctgtcag tcaactgtcaa gagattcttt tgctggcatt tcttctagaa gcaaaaag
ag
300

cgatgcgtct tttccgctga accgttccag caaaaaagac taccaacgca atatggat
tg
360

tcagaatcat ataaaagaga agcaaataac tccttgtctt gtatcaattg cattataa
ta
420

tcttcttggt agtgcaatat catatagaag tcatcgaaat agatattaag aaaaacaa
ac
480

tgtacaatca atcaatcaat catcacataa aatgttcaaa gcttggcgcc gaattcgt
cg
540

acccggggat ccgcggccgc aggcttaa atgatctagag ctttggactt cttcgcca
ga
600

ggtttggtca agtctccaat caaggttgtc ggcttgtcta ccttgccaga aatttacg

aa
660

aagatggaaa aggggtcaaata cgttggtaga tacgttggtg acacttctaa ataagcga
at
720

ttcttatgat ttatgatattt tattattaaa taagttataa aaaaaataag tgtatata
aa
780

ttttaaagtg actcttaggt tttaaaacga aaattcttgt tcttgagtaa ctctttcc
tg
840

taggtcaggt tgctttctca ggtatagcat gaggtcgctc ttattgacca cacctcta
cc
900

ggcatgccca tgggttaact gatcaatgca tcctgcatgg cgcgcctgat gagcctga
ac
960

tgcccgggca aatcagctgg acgtctgcct gcattaatga atcgccaac gcgcgggg
ag
1020

aggcggtttg cgtattgggc gctcttcgc ttctcgctc actgactcgc tgcgctcg
gt
1080

cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg gtaatacggg tatccaca
ga
1140

atcaggggat aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagg ccaggaac
cg
1200

taaaaaggcc gcgttgctgg cgtttttcca taggctcgc cccctgacg agcatcac
aa
1260

aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat accaggcg
tt
1320

tccccctgga agctccctcg tgcgctctcc tgttcgacc ctgccgctta ccggatac
ct
1380

gtccgccttt ctcccttcgg gaagcgtggc gctttctcat agctcacgct gtaggtat

ct
1440
cagttcgggtg taggtcgttc gctccaagct gggctgtgtg cacgaacccc ccgttcag
cc
1500
cgaccgctgc gccttatecg gtaactatcg tcttgagtcc aaccgggtaa gacacgac
tt
1560
atcgccaactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg taggcggg
gc
1620
tacagagtcc ttgaagtggg ggcctaacta cggctacact agaaggacag tatttggt
at
1680
ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt gatccggc
aa
1740
acaaaccacc gctggtagcg gtgggtttttt tgtttgcaag cagcagatta cgcgcaga
aa
1800
aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc agtggaac
ga
1860
aaactcacgt taagggattt tggatcatgag attatcaaaa aggatcttca cctagatc
ct
1920
tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa cttgggtc
ga
1980
cagttaccaa tgcttaatca gtgaggcacc tatctcagcg atctgtctat ttcggtca
tc
2040
catagttgcc tgactccccg tcgtgtagat aactacgata cgggaggggt taccatct
gg
2100
ccccagtgt gcaatgatac cgcgagaccc acgctcaacc gctccagatt tatcagca
at
2160
aaaccagcca gccggaaggg ccgagcgcag aagtgggtcct gcaactttat ccgcctcc

at
2220

ccagtctatt aattggtgcc gggaagctag agtaagtagt tcgccagtta atagtttg
cg
2280

caacgttggt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg gtatggct
tc
2340

attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt tgtgcaaa
aa
2400

agcggttagc tccttcgggc ctccgatcgt tgtcagaagt aagttggccg cagtgtta
tc
2460

actcatgggt atggcagcac tgcataattc tcttactgtc atgccatccg taagatgc
tt
2520

ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc ggcgaccg
ag
2580

ttgctcttgc ccggcgtcaa tacgggataa taccgcgcca catagcagaa ctttaaaa
gt
2640

gtcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac cgctgttg
ag
2700

atccagttcg atgtaaccca ctctgcacc caactgatct tcagcatctt ttactttc
ac
2760

cagcgtttct gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg gaataagg
gc
2820

gacacggaaa tggtgaatac tcatactctt cctttttcaa tattattgaa gcatttat
ca
2880

gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata aacaaata
gg
2940

ggttcgcgc acatttcccc gaaaagtgcc acctgacgcg ccctgtagcg ggcatta

ag
3000

cgcgggcgggt gtggtgggta cgcgcagcgt gaccgctaca cttgccagcg ccctagcg
cc
3060

cgctcctttc gctttcttcc cttcctttct cgccaagtgc gccggctttc cccgtcaa
gc
3120

tctaaatcgg gggctccctt taggggtccg atttagtgct ttacggcacc tcgacccc
aa
3180

aaaacttgat tagggatgat gttcacgtag tggggccatcg ccctgataga cggttttt
cg
3240

ccctttgacg ttggagtcca cgttctttaa tagtggactc ttgttccaaa ctggaaca
ac
3300

actcaaccct atctcgggtct attcttttga tttataaggg attttgccga tttcggcc
ta
3360

ttggttaaaa aatgagctga ttttaacaaaa atttaacgcg aattttaaca aaatatta
ac
3420

gcttacaatt tccattcgcc attcaggctg cgcaactgtt gggaagggcg atcgggtgc
gg
3480

gcctcttcgc tattacgcca g
3501

<210> 3
<211> 4188
<212> DNA
<213> Synthetic

<220>
<221> misc_feature
<222> (2673)..(3530)
<223> Ampicillin resistance gene

<220>

<221> rep_origin
<222> (1730)..(2670)
<223> ColE1

<220>
<221> misc_feature
<222> (3662)..(4118)
<223> f1-phage origin of replication

<220>
<221> terminator
<222> (1027)..(1355)
<223> ADH1

<220>
<221> promoter
<222> (582)..(969)
<223> Met25 promoter

<220>
<221> misc_feature
<222> (1365)..(1603)
<223> ARS1 (autonomous replicating sequence) for Yeast replication

<220>
<221> misc_feature
<222> (49)..(574)
<223> lambda spacer DNA (22428-22923)

<400> 3
ctgatttgcc cgggcagttc aggctcatca ggcgcgccat gcagggattc tggaaatt
gc
60

aacgaaggaa gaaacctcgt tgctggaagc ctggaagaag tatcggtgtg tgctgaac
cg
120

tgttgatata tcaactgcac ctgatattga gtggcctgct gtccctgtta tggagtaa
tc
180

gttttgatgat atgccgcaga aacgttgat gaaataacgt tctgcggtta gttagtat
at
240

tgtaaagctg agtattgggt tatttggcga ttattatctt caggagaata atggaagt
tc
300

tatgactcaa ttgttcatag tgtttacatc accgccaatt gcttttaaga ctgaacgc
at
360

gaaatatggt ttttcgtcat gttttgagtc tgctgttgat atttctaaag tcggtttt
tt
420

ttcttcgttt tctctaacta ttttccatga aatacatttt tgattattat ttgaatca
at
480

tccaattacc tgaagtcttt catctataat tggcattgta tgtattgggt tattggag
ta
540

gatgcttgct tttctgagcc atagctctga tctcagatct tcttcggatg caagggtt
cg
600

aatcccttag ctctcattat tttttgcttt ttctcttgag gtcacatgat cgcaaat
gg
660

caaatggcac gtgaagctgt cgatattggg gaactgtggt ggttggcaaa tgactaat
ta
720

agttagtcaa ggcgccatcc tcatgaaaac tgtgtaacat aataacogaa gtgtcgaa
aa
780

ggtggcacct tgtccaattg aacacgctcg atgaaaaaaaa taagatatat ataagggt
aa
840

gtaaagcgtc tgttagaaag gaagtttttc ctttttcttg ctctcttgtc ttttcac
ta
900

ctatttcctt cgtgtaatac agggtcgtca gatacataga tacaattcta ttaccccc
at
960

ccatacaagc ttggcgccga attcgtcgac ccggggatcc gcggccgcag gcctaaat
tg
1020

atctagagct ttggacttct tcgccagagg tttggtcaag tctccaatca aggttgtc
gg
1080

cttgtctacc ttgccagaaa tttacgaaaa gatggaaaag ggtcaaatacg ttggtaga
ta
1140

cgttgttgac acttctaaat aagcgaattt cttatgattt atgattttta ttattaaa
ta
1200

agttataaaa aaaataagtg tatacaaatt ttaaagtgac tcttaggttt taaaacga
aa
1260

attcttggtc ttgagtaact ctttcctgta ggtcagggtg ctttctcagg tatagcat
ga
1320

ggtcgctctt attgaccaca cctctaccgg catgcccattg gggtcttttg aaaagcaa
gc
1380

ataaaagatc taaacataaa atctgtaaaa taacaagatg taaagataat gctaaatc
at
1440

ttggcttttt gattgattgt acaggaaaat atacatcgca ggggggttgac tttacca
tt
1500

tcaccgcaat ggaatcaaac ttgttgaaga gaatgttcac aggcgcatac gctacaat
ga
1560

cccgattctt gctagccttt tctcggctctt gcaaacaacc gccaaactgat caatgcac
cc
1620

tgcattgggc gctgatgag cctgaactgc cggggcaaata cagctggacg tctgcctg
ca
1680

ttaatgaatc ggccaacgcg cggggagagg cggtttgctt attgggcgct cttccgct
tc
1740

ctcgetcaat gactcgetgc gctcggctctt tcggctgcgg cgagcgggtat cagctcac
tc
1800

aaaggcggta atacggttat ccacagaatc aggggataac gcaggaaaga acatgtga
gc
1860

aaaaggccag caaaaggcca ggaaccgtaa aaaggccgcg ttgctggcgt ttttccat
ag
1920

gctccgcccc cctgacgagc atcacaaaaa tcgacgctca agtcagaggt ggcgaaac
cc
1980

gacaggacta taaagatacc aggcgtttcc ccttgggaagc tccctcgtgc gctctcct
gt
2040

tccgaccctg ccgcttaccg gatacctgtc cgcctttctc ccttcgggaa gcgtggcg
ct
2100

ttctcatagc tcacgctgta ggtatctcag ttcggtgtag gtcgttcgct ccaagctg
gg
2160

ctgtgtgcac gaaccccccg ttcagcccgga ccgctgcgcc ttatccggta actatcgt
ct
2220

tgagtccaac ccggttaagac acgacttata gccactggca gcagccactg gtaacagg
at
2280

tagcagagcg aggtatgtag gcggtgctac agagttcttg aagtgggtggc ctaactac
gg
2340

ctacactaga aggacagtat ttggtatctg cgctctgctg aagccagtta ccttcgga
aa
2400

aagagttggg agctcttgat ccggcaaaca aaccaccgct ggtagcgggtg gttttttt
gt
2460

ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt tgatcttt
tc
2520

tacggggctc gacgctcagt ggaacgaaaa ctcacgttaa gggattttgg tcatgaga
tt
2580

atcaaaaagg atcttcacct agatcctttt aaattaaaaa tgaagtttta aatcaatc
ta
2640

aagtatatat gagtaaactt ggtctgacag ttaccaatgc ttaatcagtg aggcacct
at
2700

ctcagcgatc tgtctatttc gttcatccat agttgcctga ctccccgtcg tgtagata
ac
2760

tacgatacgg gagggcttac catctggccc cagtgtgca atgataccgc gagacca
cg
2820

ctcaccggct ccagatttat cagcaataaa ccagccagcc ggaagggccg agcgcaga
ag
2880

tggtcctgca actttatccg cctccatcca gtctattaat tggtgccggg aagctaga
gt
2940

aagtagttcg ccagttaata gtttgcgcaa cgttgttgcc attgctacag gcacgtg
gt
3000

gtcacgctcg tcgtttggta tggcttcatt cagctccggc tccaacgat caaggcga
gt
3060

tacatgatcc cccatgttgt gcaaaaaagc ggtagctcc ttcggctctc cgatcgtt
gt
3120

cagaagtaag ttggccgcag tggtatcact catgggtatg gcagcactgc ataattct
ct
3180

tactgtcatg ccatccgtaa gatgcttttc tgtgactggg gagtactcaa ccaagtca
tt
3240

ctgagaatag tgtatgcggc gaccgagttg ctcttgcccg gcgtcaatac gggataat
ac
3300

cgcgccacat agcagaactt taaaagtgt catcattgga aaacgttctt cggggcga
aa
3360

actctcaagg atcttaccgc tgttgagatc cagttcgatg taaccactc gtgcaccc
aa
3420

ctgatcttca gcactcttta ctttcaccag cgtttctggg tgagcaaaaa caggaagg
ca
3480

aaatgccgca aaaaaggga taagggcgac acggaaatgt tgaatactca tactcttc
ct
3540

ttttcaatat tattgaagca tttatcaggg ttattgtctc atgagcggat acatattt
ga
3600

atgtatttag aaaaataaac aaataggggt tccgcgcaca tttcccgaa aagtgcc
cc
3660

tgacgcgccc tgtagcggcg cattaagcgc ggcgggtgtg gtggttacgc gcagcgtg
ac
3720

cgctacaact gccagcgcgc tagcgcgcgc tcctttcgct ttcttccctt cctttctc
gc
3780

cacgttcgcc ggctttcccc gtcaagctct aaatcggggg ctccctttag ggttcgga
tt
3840

tagtgcttta cggcacctcg acccaaaaa acttgattag ggtgatggtt cacgtagt
gg
3900

gccatcgccc tgatagacgg tttttcgccc tttgacgttg gagtccacgt tctttaat
ag
3960

tggactcttg ttccaaactg gaacaacact caaccctatc tcggtctatt cttttgat
tt
4020

ataagggatt ttgccgattt cggcctattg gttaaaaaat gagctgattt aacaaaaa
tt
4080

taacgcgaat ttaacaaaa tattaacgct tacaatttcc attcgccatt caggctgc
gc
4140

aactgttggg aagggcgatc ggtgcggggc tcttcgctat tacgccag

4188

<210> 4
<211> 11466
<212> DNA
<213> Synthetic

<220>
<221> misc_feature
<222> (3560)..(4247)
<223> Tetrahymena thermophila macronuclear telomere

<220>
<221> misc_feature
<222> (6024)..(6711)
<223> Tetrahymena thermophila macronuclear telomere

<220>
<221> misc_feature
<222> (9644)..(10388)
<223> Autonomous replicating sequence

<220>
<221> misc_feature
<222> (10488)..(11465)
<223> Centromere IV

<220>
<221> rep_origin
<222> (7198)..(7198)
<223> Origin of replication, PMB1

<220>
<221> misc_feature
<222> (1962)..(2765)
<223> URA3, orotidine-5'-phosphate decarboxylase coding sequence

<220>
<221> misc_feature
<222> (4893)..(5552)
<223> HIS3, imidazoleglycerolphosphate dehydratase, coding sequence

uence

<220>
<221> misc_feature
<222> (7956)..(8816)
<223> AP(R), beta-lactamase, ampR ampicillin resistance, coding
sequence
e

<220>
<221> misc_feature
<222> (9129)..(9803)
<223> TRP1, phosphoribosylanthranilate isomerase, coding sequence

<400> 4
ttctcatggt tgacagctta tcacgataa gctttaatgc ggtagtttat cacagtta
aa
60

ttgctaacgc agtcaggcac cgtgtatgaa atctaacaat gcgctcatcg tcacctc
gg
120

caccgtcacc ctggatgctg taggcatagg cttgggtatg ccggtactgc cgggcctc
tt
180

gcgggatatc gtccattcgc acagcatcgc cagtcaactat ggcgtgctgc tagcgcta
ta
240

tgcgttgatg caatttctat gcgcaccgct tctcggagca ctgtccgacc gctttggc
cg
300

ccgcccagtc ctgctcgctt cgctacttgg agccactatc gactacgcga tcatggcg
ac
360

cacaccgctc ctgtggatca attcccttta gtataaattt cactctgaac catcttgg
aa
420

ggaccggtaa ttatttcaaa tctctttttc aattgtatat gtgttatggt atgtagta
ta
480

ctctttcttc aacaattaaa tactctcggt agccaagttg gtttaaggcg caagactt
ta
540

atttatcaact acggaattgg cgcgccaatt ccgtaatctt gagatcgggc gttcgatc
gc
600

cccgggagat ttttttgttt tttatgtctt ccattcactt cccagacttg caagttga
aa
660

tatttctttc aagggaattg atcctctacg ccggacgcat cgtggccggc atcacccg
cg
720

ccacaggtgc ggttgctggc gcctatatcg ccgacatcac cgatggggaa gatcgggc
tc
780

gccacttcgg gctcatgagc gcttgtttcg gcgtgggtat ggtggcaggc cccgtggc
cg
840

ggggactggt gggcgccatc tccttgcatg caccattcct tgcggcgggc gtgctcaa
cg
900

gcctcaacct actactgggc tgcttcctaa tgcaggagtc gcataaggga gagcgtcg
ac
960

cgatgccctt gagagccttc aaccagtcg gctccttcg gtgggcggcg ggcgatgac
ta
1020

tcgtcgccgc acttatgact gtcttcttta tcatgcaact cgtaggacag gtgccggc
ag
1080

cgctctgggt cattttcggc gaggaccgtt ttogctggag cgcgacgatg atcggcct
gt
1140

cgcttgccgt attcggaatc ttgcacgccc tcgctcaagc cttcgtcact ggtcccgc
ca
1200

caaacgttt cggcgagaag caggccatta tcgccggcat ggcggccgac gcgctggg
ct
1260

acgtcttgct ggcgttcgcg acgcgaggct ggatggcctt ccccattatg attcttct
cg
1320

cttcggcgcg catcgggatg cccgcgttgc aggccatgct gtccaggcag gtagatga
cg
1380

accatcaggg acagcttcaa ggatcgctcg cggctcttac cagcctaact tcgatcac
tg
1440

gaccgctgat cgtcacggcg atttatgccg cctcggcgag cacatggaac gggttggc
at
1500

ggattgtagg cgccgccta taccttgtct gcctccccgc gttgcgtcgc ggtgcatg
ga
1560

gccggggccac ctcgacctga atggaagccg gcggcacctc gctaacggat tcaccact
cc
1620

aagaattgga gccaatcaat tcttgcgag aactgtgaat gcgcaaacca acccttgg
ca
1680

gaacatatcc atcgcgtccg ccatctccag cagccgcacg cggcgcatcc cccccccc
ct
1740

ttcaattcaa ttcattttt tttttttatt cttttttttg atttcggttt ctttgaaa
tt
1800

tttttgattc ggtaattctcc gaacagaagg aagaacgaag gaaggagcac agacttag
at
1860

tggtatatat acgcatatgt agtgttgaag aaacatgaaa ttgccagta ttcttaac
cc
1920

aactgcacag aacaaaaacc tgcaggaaac gaagataaat catgtcgaaa gctacata
ta
1980

aggaacgtgc tgctactcat cctagtctg ttgctgcaa gctatttaac atcatgca
cg
2040

aaaagcaaac aaacttgtgt gcttcattgg atgttcgtac caccaaggaa ttactgga
gt
2100

tagttgaagc attaggtccc aaaatttgtt tactaaaaac acatgtggat atcttgac
tg
2160

atttttccat ggagggcaca gttaagccgc taaaggcatt atccgccaag tacaattt
tt
2220

tactcttcga agacagaaaa tttgctgaca ttggtaatac agtcaaattg cagtactc
tg
2280

cgggtgtata cagaatagca gaatgggcag acattacgaa tgcacacggt gtgggtggg
cc
2340

caggtattgt tagcggtttg aagcaggcgg cagaagaagt aacaaaggaa cctagagg
cc
2400

ttttgatgtt agcagaattg tcatgcaagg gctccctatc tactggagaa tatactaa
gg
2460

gtactgttga cattgcgaag agcgacaaag attttgttat cggctttatt gctcaaag
ag
2520

acatgggtgg aagagatgaa ggttacgatt gggtgattat gacacccggt gtgggttt
ag
2580

atgacaaggg agacgcattg ggtcaacagt atagaaccgt ggatgatgtg gtctctac
ag
2640

gatctgacat tattattgtt ggaagaggac tatttgcaaa gggaagggat gctaagg
ag
2700

aggggtgaacg ttacagaaaa gcaggctggg aagcatattt gagaagatgc ggccagca
aa
2760

actaaaaaac tgtattataa gtaaatgcat gtatactaaa ctcacaaatt agagcttc
aa
2820

tttaattata tcagttatta ctccggcgta atgattttta taatgacgaa aaaaaaaa
aa
2880

ttggaaagaa aagggggggg gggcagcgtt gggtcctggc cacgggtgcg catgatcg
tg
2940

ctcctgtcgt tgaggaccgc gctaggctgg cgggggttgc ttactgggta gcagaatg
aa
3000

tcaccgatac gcgagcgaac gtgaagcgac tgctgctgca aaacgtctgc gacctgag
ca
3060

acaacatgaa tgggtcttcg tttccgtgtt tcgtaaagtc tggaaacgcg gaagtcag
cg
3120

ccctgcacca ttatgttcgc gatctgcac gcaggatgct gctggctacc ctgtggaa
ca
3180

cctacatctg tattaacgaa gcgctggcat tgaccctgag tgatttttct ctggtccc
gc
3240

cgcaccata ccgccagtg tttaccctca caacgttcca gtaaccgggc atgttcac
ca
3300

tcagtaaccc gtatcgtgag catcctctct cgtttcacgc gtatcattac ccccatga
ac
3360

agaaattccc ccttacacgc aggcacaaag tgaccaaaca ggaaaaaacc gcccttaa
ca
3420

tggeccgctt tatcagaagc cagacattaa cgcttctgga gaaactcaac gagctgga
cg
3480

cggatgaaca ggcagacatc tgtgaatcgc ttcacgacca cgctgatgag ctttaccg
ca
3540

gccctcgagg gataagcttc attttttagat aaaatttatt aatcatcatt aatttctt
ga
3600

aaaacatttt atttattgat cttttataac aaaaaaccct tctaaaagtt tatttttg
aa

3660

tgaaaaactt ataaaaattt atgaaaaacta caaaaaataa aattttttaat taaaataa
tt

3720

ttgataagaa cttcaatctt tgactagcta gcttagtcat ttttgagatt taattaat
at

3780

tttatgttta ttcatatata aactattcaa aatattatag aatttaaaca ttttaaca
tc

3840

ttaatcattc ataaataact aaaaatcaaa gtattacatc aataaataac ttttactc
aa

3900

tgtcaaagaa ttattggggg tgggggttggg gttgggggttg ggggttggggg tgggggttg
gg

3960

gttgggggttg ggggttggggg tgggggttggg gttgggggttg ggggttggggg tgggggttg
gg

4020

gttgggggttg ggggttggggg tgggggttggg gttgggggttg ggggttggggg tgggggttg
gg

4080

gttgggggttg ggggttggggg tgggggttggg gttgggggttg ggggttggggg tgggggttg
gg

4140

gttgggggttg ggggttggggg tgggggttggg gttgggggttg ggggtgggaaa acagcatt
ca

4200

gggtattagaa gaatatcctg attcaggtga aaatattggt gatgcgcggg atcctcgg
gg

4260

acaccaaata tggcgatctc ggccttttcg tttcttggag ctgggacatg tttgccat
cg

4320

atccatctac caccagaacg gccgttagat ctgctgccac cgttgtttcc accgaaga
aa

4380

ccaccgttgc cgtaaccacc acgacggttg ttgctaaaga agctgccacc gccacggc
ca
4440

ccgttgtagc cgccgttggt gttattgtag ttgctcatgt tatttctggc acttcttg
gt
4500

tttctcttta agtgaggagg aacataacca ttctcgttgt tgctcgttgat gcttaaat
tt
4560

tgcacttggt cgctcagttc agccataata tgaaatgctt ttcttggtgt tcttacgg
aa
4620

taccaattgc cacctatcac cacaactaac tttttcccg tctccatct cttttata
tt
4680

ttttttctcg atcgagttca agagaaaaaa aaagaaaaag caaaaagaaa aaaggaaa
gc
4740

gcgcctcgtt cagaatgaca cgtatagaat gatgcattac cttgtcatct tcagtatc
at
4800

actgttcgta tacatactta ctgacattca taggtataca tatatacaca tgtatata
ta
4860

tctgtatgctg cagcttttaa taatcgggtg cactacataa gaacaccttt ggtggagg
ga
4920

acatcgttgg taccattggg cgaggtggct tctcttatgg caaccgcaag agccttga
ac
4980

gcactctcac tacggtgatg atcattcttg cctcgcagac aatcaacgtg gagggtaa
tt
5040

ctgctagcct ctgcaaagct ttcaagaaaa tgcgggatca tctcgcaaga gagatctc
ct
5100

actttctccc ttgcaaacc aagttcgaca actgcgtacg gcctgttcga aagatcta
cc
5160

accgctctgg aaagtgcctc atccaaaggc gcaaatacctg atccaaacct ttttactc
ca
5220

cgcgccagta gggcctcttt aaaagcttga ccgagagcaa tcccgcagtc ttcagtgg
tg
5280

tgatggtcgt ctatgtgtaa gtcaccaatg cactcaacga ttagcgacca gccggaat
gc
5340

ttggccagag catgtatcat atgggccaga aaccctatac ctgtgtggac gttaatca
ct
5400

tgcgattgtg tggcctgttc tgctactgct tctgcctctt tttctgggaa gatcgagt
gc
5460

tctatcgcta ggggaccacc ctttaaagag atcgcaatct gaatcttggg ttcatttg
ta
5520

atacgcttta ctagggcttt ctgctctgtc atctttgcct tcgtttatct tgccctgct
ca
5580

ttttttagta tattcttcga agaaatcaca ttactttata taatgtataa ttcattat
gt
5640

gataatgcca atcgctaaga aaaaaaaga gtcataccgct aggtggaaaa aaaaaaat
ga
5700

aaatcattac cgaggcataa aaaaatatag agtgtactag aggaggccaa gagtaata
ga
5760

aaaagaaaat tgcgggaaag gactgtgtta tgacttcctt gactaatgcc gtgttcaa
ac
5820

gatacctggc agtgactcct agcgctcacc aagctcttaa aacgagaatt aagaaaaa
gt
5880

cgatcatcttt cgataagttt ttcccacagc aaagcaatag tagaaaaaaa caatggga
aa
5940

cgttgaatga agacaaagcg tcgtgggttta aaaggaaata cgctcacgta catgctag
gg
6000

aacaggaccg tgcagcggat cccgcgcac cacaatattt tcacctgaat caggatat
tc
6060

ttctaatacc tgaatgctgt tttcccaccc caaccccaac cccaacccca accccaac
cc
6120

caaccccaac cccaacccca accccaaccc caaccccaac cccaacccca accccaac
cc
6180

caaccccaac cccaacccca accccaaccc caaccccaac cccaacccca accccaac
cc
6240

caaccccaac cccaacccca accccaaccc caaccccaac cccaacccca accccaac
cc
6300

caaccccaac cccaacccca accccaaccc caaccccaac cccaacccca accccaat
aa
6360

ttctttgaca ttgagtaaaa gttatttatt gatgtaatac tttgattttt agttattt
at
6420

gaatgattaa gatgttaaaa tgtttaaatt ctataatatt ttgaatagtt tatatatg
aa
6480

taaacataaa atattaatta aatctcaaaa atgactaagc tagctagtca aagattga
ag
6540

ttcttatcaa aattatttta attaaaaatt ttattttttg tagttttcat aaattttt
at
6600

aagtttttca ttcaaaaata aactttttaga agggtttttt gttataaaaag atcaataa
at
6660

aaaatgtttt tcaagaaatt aatgatgatt aataaatttt atctaaaaat gaagctta
tc
6720

cctcgagggc tgcctcgcg cgttcggtga tgacggtgaa aacctctgac acatgcag
ct
6780

cccgagacg gtcacagctt gtctgtaagc ggatgccggg agcagacaag cccgtcag
gg
6840

cgcgtcagcg ggtgttggcg ggtgtcgggg cgcagccatg acccagtcac gtagcgat
ag
6900

cggagtgtat actggcttaa ctatgcggca tcagagcaga ttgtactgag agtgcacc
at
6960

atgcgggtgtg aaataccgca cagatgcgta aggagaaaat accgcatcag gcgctctt
cc
7020

gcttcctcgc tcaactgactc gctgcgctcg gtcgttcggc tgcggcgagc ggtatcag
ct
7080

cactcaaagg cggtaatacg gttatccaca gaatcagggg ataacgcagg aaagaaca
tg
7140

tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttt
tc
7200

cataggctcc gccccctga cgagcatcac aaaaatcgac gctcaagtca gaggtggc
ga
7260

aaccgcagag gactataaag ataccaggcg tttccccctg gaagctccct cgtgcgct
ct
7320

cctgttccga cctgcccgt taccggatac ctgtccgctt ttctcccttc gggaagcg
tg
7380

gcgctttctc atagctcacg ctgtaggtat ctgagttcgg tgtaggtcgt tcgctcca
ag
7440

ctgggctgtg tgcacgaacc ccccggtcag cccgaccgct gcgccttate cggtaact
at
7500

cgtcttgagt ccaacccggt aagacacgac ttatcgccac tggcagcagc cactggta
ac
7560

aggattagca gagcgaggta tgtaggcggt gctacagagt tcttgaagtg gtggccta
ac
7620

tacggctaca ctagaaggac agtatttggt atctgcgctc tgctgaagcc agttacct
tc
7680

ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag cgggtggtt
tt
7740

tttgtttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcctttga
tc
7800

ttttctacgg ggtctgacgc tcagtggaaac gaaaactcac gttaagggat tttggtca
tg
7860

agattatcaa aaaggatctt cacctagatc cttttaaatt aaaaatgaag ttttaa
ca
7920

atctaaagta tatatgagta aacttgggtc gacagttacc aatgcttaat cagtgagg
ca
7980

cctatctcag cgatctgtct atttcgttca tccatagtgt cctgactccc cgtcgtgt
ag
8040

ataactacga tacgggaggg cttaccatct ggccccagtg ctgcaatgat accgcgag
ac
8100

ccacgctcac cggctocaga tttatcagca ataaaccagc cagccggaag ggccgagc
gc
8160

agaagtggtc ctgcaacttt atccgcctcc atccagtcta ttaattgttg ccgggaag
ct
8220

agagtaagta gttcgccagt taatagtttg cgcaacgttg ttgccattgc tgcaggca
tc
8280

gtggtgtcac gctcgtcgtt tggatatggt tcattcagct ccggttccca acgatcaa
gg
8340

cgagttacat gatcccccat gttgtgcaaa aaagcgggta gtccttcgg tcctccga
tc
8400

gttgtcagaa gtaagttggc cgcagtggtt tcactcatgg ttatggcagc actgcata
at
8460

tctcttactg tcatgccatc cgtaagatgc ttttctgtga ctggtgagta ctcaacca
ag
8520

tcattctgag aatagtgtat ggggcgaccg agttgctctt gcccggcgtc aacacggg
at
8580

aataccgcgc cacatagcag aactttaaaa gtgctcatca ttggaaaacg ttcttcgg
gg
8640

cgaaaactct caaggatctt accgctgttg agatccagtt cgatgtaacc cactcgtg
ca
8700

cccaactgat cttcagcatc ttttactttc accagcgttt ctgggtgagc aaaaacag
ga
8760

aggcaaaatg ccgcaaaaaa gggaataagg gcgacacgga aatgttgaat actcatac
tc
8820

ttcctttttc aatattattg aagcatttat cagggttatt gtctcatgag cggataca
ta
8880

tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaag
tg
8940

ccacctgacg tctaagaaac cattattatc atgacattaa cctataaaaa taggcgta
tc
9000

acgaggccct ttcgtcttca agaattaatt cggtcgaaaa aagaaaagga gagggcca
ag
9060

agggagggca ttggtgacta ttgagcacgt gagtatacgt gattaagcac acaaaggc
ag
9120

cttgaggtat gtctgttatt aatttcacag gtagttctgg tccattgggtg aaagtttg
cg
9180

gcttgacagag cacagaggcc gcagaatgtg ctctagattc cgatgctgac ttgctggg
ta
9240

ttatatgtgt gcccaataga aagagaacaa ttgacccggt tattgcaagg aaaatttc
aa
9300

gtcttgtaaa agcatataaa aatagttcag gcactccgaa atacttggtt ggcgtggt
tc
9360

gtaatcaacc taaggaggat gttttggctc tggatcaatga ttacggcatt gatatcgt
cc
9420

aactgcatgg agatgagtcg tggcaagaat accaagagtt cctcggtttg ccagttat
ta
9480

aaagactcgt atttccaaaa gactgcaaca tactactcag tgcagcttca cagaaacc
tc
9540

attcgtttat tcccttgttt gattcagaag caggtgggac aggtgaactt ttggattg
ga
9600

actcgatttc tgactgggtt ggaaggcaag agagccccga aagcttacat tttatggt
ag
9660

ctggtggact gacgccagaa aatggttggtg atgcgcttag attaaatggc gttattgg
tg
9720

ttgatgtaag cggaggtgtg gagacaaatg gtgtaaaaga ctctaacaaa atagcaaa
tt
9780

tctgcaaaaa tgctaagaaa taggttatta ctgagtagta tttatttaag tattgttt
gt
9840

gcacttgccct gcaggccttt tgaaaagcaa gcataaaaga tctaaacata aaatctgt
aa
9900

aataacaaga tgtaaagata atgctaaatc atttggtttt ttgattgatt gtacagga
aa
9960

atatacatcg caggggggttg actttttacca tttcacgcga atggaatcaa acttggtg
aa
10020

gagaatgttc acaggcgcat acgctacaat gacccgattc ttgctagcct tttctcgg
tc
10080

ttgcaaacaa ccgccggcag cttagtatat aaatacacat gtacatacct ctctccgt
at
10140

cctcgtaatc attttcttgt atttatcgtc ttttcgctgt aaaaacttta tcacactt
at
10200

ctcaaataca cttattaacc gcttttacta ttatcttcta cgctgacagt aatatcaa
ac
10260

agtgcacat attaaacaca gtgggtttctt tgcataaaca ccatcagcct caagtcgt
ca
10320

agtaaagatt tcgtgttcac gcagatagat aacaatctat atgttgataa ttagcggt
gc
10380

ctcatcaatg cgagatccgt ttaaccggac cctagtgcac ttaccccacg ttcgggtcc
ac
10440

tgtgtgccga acatgctcct tcactatttt aacatgtgga attaattcta aatcctct
tt
10500

atatgatctg ccgatagata gttctaagtc attgaggttc atcaacaatt ggattttc
tg
10560

tttactcgac ttcaggtaaa tgaaatgaga tgatacttgc ttatctcata gttaaactc
ta
10620

agaggtgata cttatittact gtaaaactgt gacgataaaa ccggaaggaa gaataaga
aa
10680

actcgaactg atctataatg cctatitttct gtaaagagtt taagctatga aagcctcg
gc
10740

attttggccg ctccataggta gtgctttttt tccaaggaca aaacagtttc tttttctt
ga
10800

gcagggtttta tgtttcggta atcataaaca ataaataaat tatttcattt atgtttaa
aa
10860

ataaaaaata aaaaagtatt ttaaattttt aaaaaagttg attataagca tgtgacct
tt
10920

tgcaagcaat taaattttgc aatttgtgat tttaggcaaa agttacaatt tctggctc
gt
10980

gtaatatatg tatgctaaag tgaactttta caaagtcgat atggacttag tcaaaaga
aa
11040

ttttcttaaa aatatatagc actagccaat ttagcacttc tttatgagat atattata
ga
11100

ctttattaag ccagatttgc gtattatatg tatttaccgc gcgaatcatg gacataca
tt
11160

ctgaaatagg taatattctc tatggtgaga cagcatagat aacctaggat acaagtta
aa
11220

agctagtact gttttgcagt aatttttttc ttttttataa gaatgttacc acctaat
aa
11280

gttataaagt caatagttaa gtttgatatt tgattgtaaa ataccgtaat atatttgc
at
11340

gatcaaaagg ctcaatgttg actagccagc atgtcaacca ctatattgat caccgata
ta
11400

tggacttcca caccaactag taatatgaca ataaattcaa gatattcttc atgagaat
gg
11460

cccaga

11466